<?xml version="1.0" encoding="UTF-8" ?>
<feed xmlns="http://www.w3.org/2005/Atom">
    <link href="https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/?sAtom=1" rel="self" type="application/atom+xml" />
    <author>
        <name>mhp_medien</name>
    </author>
    <title>Blog / Atom Feed</title>
    <id>https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/?sRss=1</id>
    <updated>2026-04-24T16:51:01+02:00</updated>
    
        <entry>
            <title type="text">Ausgabe 1.2026 | Zeitschrift für Infektionstherapie</title>
            <id>https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/ausgabe-1.2026-zeitschrift-fuer-infektionstherapie</id>
            <link href="https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/ausgabe-1.2026-zeitschrift-fuer-infektionstherapie"/>
            <summary type="html">
                <![CDATA[
                
                                            Hier finden Sie die aktuellen Literaturnachweise der Rubrik &quot;Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie&quot; mit dem Beitrag &quot;Die Gefahr lauert im Swimmingpool&quot; der Ausgabe 1.2026 der Zeitschrift für Infektionstherapie. 
                                        ]]>
            </summary>
            <content type="html">
                <![CDATA[
                    Rubrik: Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie     
   Die Gefahr lauert im Swimmingpool (S. 2)     
 1.&amp;nbsp; &amp;nbsp; Bild.de (02.04.2025).  https://www.bild.de/news/ausland/kind-nach-planschen-im-pool-tot-es-starb-an-hirnfressender-amoebe-67e94a257ccb4912b1bff6c1   2.&amp;nbsp; &amp;nbsp; Bild.de (08.06.2025).  https://www.bild.de/leben-wissen/medizin/nach-nasenspuelung-frau-stirbt-an-hirnfresser-amoebe-6845b3baeaf9b317dbcfd362   3.&amp;nbsp; &amp;nbsp; Bild.de (21.06.2025)  https://www.bild.de/news/ausland/nach-schwimmbad-besuch-junge-11-stirbt-durch-hirnfressende-amoebe-6853c3989725c2004ffbfeb2   4.&amp;nbsp; &amp;nbsp; Obituaries: Malcolm Charles Fowler M.D. (Adel.), F.R.C.P.A., F.R.A.C.P. Pathology 1975; 7 (2): 166-168. doi: 10.3109/00313027509092714.  5.&amp;nbsp; &amp;nbsp; Fowler M, Carter RF. Acute pyogenic meningitis probably due to Acanthamoeba sp.: a preliminary report. Br Med J. 1965; 2 (5464): 740-742. doi: 10.1136/bmj.2.5464.734-a.  6.&amp;nbsp; &amp;nbsp; Gharpure R, Bliton J, Goodman A, Ali IKM, Yoder J, Cope JR. Epidemiology and clinical characteristics of primary amebic meningoencephalitis caused by Naegleria fowleri: a global review. Clin Infect Dis 2021; 73 (1): e19-e27. doi: 10.1093/cid/ciaa520.  7.&amp;nbsp; &amp;nbsp; Gharpure R, Gleason M, Salah Z, Blackstock AJ, Hess-Homeier D, Yoder JS, Ali IKM, Collier SA, Cope JR. Geographic range of recreational water-associated primary amebic meningoencephalitis, United States, 1978-2018. Emerg Infect Dis 2021; 27 (1): 271-274. doi: 10.3201/eid2701.202119.  8.&amp;nbsp; &amp;nbsp; Bourli P, Eslahi AV, Tzoraki O, Karanis P. Waterborne transmission of protozoan parasites: a review of worldwide outbreaks - an update 2017-2022. J Water Health 2023; 21 (10): 1421-1447. doi: 10.2166/wh.2023.094.  9.&amp;nbsp; &amp;nbsp; Ghosh R, León-Ruiz M, Dubey S, Benito-León J. Naegleria fowleri in Kerala, India: prevention over panic. Lancet 2025; 406 (10514): 1945. doi: 10.1016/S0140-6736(25)01971-3.  10.&amp;nbsp; &amp;nbsp; Reuters (Stand: 09/2025).  https://www.reuters.com/business/healthcare-pharmaceuticals/surge-deadly-brain-eating-amoeba-cases-causes-alarm-indias-kerala-state-2025-09-18/   11.&amp;nbsp; &amp;nbsp; World Health Organization (WHO). Naegleria fowleri: background document for the WHO guidelines for drinking-water quality (Stand: 2025). doi: 10.2471/B09269.  https://iris.who.int/items/94a62a11-7bbc-4cad-8771-113c1c162968   12.&amp;nbsp; &amp;nbsp; Delumeau A, Allouch N, Quétel I, Nerrière V, Marcelino I. The fascinating world of free-living amoebae, these remarkably versatile protists. Med Sci (Paris). 2025; 41 (10): 743-752. doi: 10.1051/medsci/2025140.  13.&amp;nbsp; &amp;nbsp; Lau HY, Ashbolt NJ. The role of biofilms and protozoa in Legionella pathogenesis: implications for drinking water. J Appl Microbiol 2009; 107 (2): 368-78. doi: 10.1111/j.1365-2672.2009.04208.x.  14.&amp;nbsp; &amp;nbsp; Thomas V, McDonnell G, Denyer SP, Maillard JY. Free-living amoebae and their intracellular pathogenic microorganisms: risks for water quality. FEMS Microbiol Rev 2010; 34 (3): 231-259. doi: 10.1111/j.1574-6976.2009.00190.x.  15.&amp;nbsp; &amp;nbsp; Scheid P. Viruses in close associations with free-living amoebae. Parasitol Res 2015; 114 (11): 3959-9367. doi: 10.1007/s00436-015-4731-5.  16.&amp;nbsp; &amp;nbsp; Robert Koch Institut. Amöbenenzephalitis (Stand: 12/2023).  https://www.rki.de/DE/Aktuelles/Publikationen/RKI-Ratgeber/Ratgeber/Ratgeber_Amoebenenzephalitis.html   17.&amp;nbsp; &amp;nbsp; Robert Koch Institut. Amöbenenkeratitis (Stand: 07/2025).  https://www.rki.de/DE/Aktuelles/Publikationen/RKI-Ratgeber/Ratgeber/Ratgeber_Amoebenkeratitis.html   18.&amp;nbsp; &amp;nbsp; Siddiqui R, Khan NA. Primary amoebic meningoencephalitis caused by Naegleria fowleri: an old enemy presenting new challenges. PLoS Negl Trop Dis 2014; 8 (8): e3017. doi: 10.1371/journal.pntd.0003017.  19.&amp;nbsp; &amp;nbsp; Borkens Y. The pathology of the brain eating amoeba Naegleria fowleri. Indian J Microbiol 2024; 64 (3): 1384-1394. doi: 10.1007/s12088-024-01218-5.  20.&amp;nbsp; &amp;nbsp; Centers for Disease Control and Prevention (CDC). Naegleria fowlerie infections (Stand: 07/2025).  https://www.cdc.gov/naegleria/about/index.html   21.&amp;nbsp; &amp;nbsp; Centers for Disease Control and Prevention (CDC). Clinical care of Naegleria fowleri infection (Stand: 11/2025).  https://www.cdc.gov/naegleria/hcp/clinical-care/index.html   22.&amp;nbsp; &amp;nbsp; Visvesvara GS, Moura H, Schuster FL. Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol Med Microbiol 2007; 50 (1): 1-26. doi: 10.1111/j.1574-695X.2007.00232.x.  23.&amp;nbsp; &amp;nbsp; Siddiqui R, Rizvi ZS, Maciver SK, Khan NA. Balamuthia mandrillaris - a brief overview of the parasite causing encephalitis. Microb Pathog 2025; 210: 108195. doi: 10.1016/j.micpath.2025.108195.  24.&amp;nbsp; &amp;nbsp; Deutsches Institut für Normung. DIN EN ISO 14729:2011-01: Augenoptik - Kontaktlinsenpflegemittel - Mikrobiologische Anforderungen und Prüfverfahren für Produkte und Systeme zum Hygienemanagement von Kontaktlinsen (ISO 14729:2001 + Amd.1:2010); Deutsche Fassung EN ISO 14729:2001 + A1:2010. Stand: 01/2011.  25.&amp;nbsp; &amp;nbsp; Khurana S, Kanaujia R, Sharma M, Sharma C, Gupta A. Acanthamoeba keratitis beyond &quot;wear&quot; and &quot;tear:&quot; There is more than what meets the eye! Trop Parasitol 2025; 15 (2): 104-109. doi: 10.4103/tp.tp_4_25.  26.&amp;nbsp; &amp;nbsp; Blaser F, Grimm F, Baenninger PB, Gatzioufas Z, Thiel MA, Menghini M, Frueh BE, Muehlethaler K, Alder M, Hashemi K, Brouillet R, Massa H, Finger ML, Tappeiner C, Papazoglou A, Freiberg FJ, Greub G, Barthelmes D, Zweifel SA, Said S. Incidence of Acanthamoeba keratitis in Switzerland. Microorganisms 2025; 13 (9): 2032. doi: 10.3390/microorganisms13092032.  27.&amp;nbsp; &amp;nbsp; Daas L, Szentmáry N, Eppig T, Langenbucher A, Hasenfus A, Roth M, Saeger M, Nölle B, Lippmann B, Böhringer D, Reinhard T, Kelbsch C, Messmer E, Pleyer U, Roters S, Zhivov A, Engelmann K, Schrecker J, Zumhagen L, Thieme H, Darawsha R, Meyer-Ter-Vehn T, Dick B, Görsch I, Hermel M, Kohlhaas M, Seitz B. The German Acanthamoeba keratitis register: Initial results of a multicenter study. Ophthalmologe 2015; 112 (9): 752-763. doi: 10.1007/s00347-014-3225-7.  28.&amp;nbsp; &amp;nbsp; Atamna A, Franken L, Grossman T, Rozenblatt S, Tobar A, Fichman-Horn S, Zvi HB, Auriel E, Bishara J. Acanthamoeba healyi (genotype T12) meningoencephalitis in an adult - first case in Israel. Diagn Microbiol Infect Dis 2025; 113 (3): 116988. doi: 10.1016/j.diagmicrobio.2025.116988.  29.&amp;nbsp; &amp;nbsp; Pramanik S, Dasgupta S, Samui S, Chandra A, Kattady FJ, Makhal M. Acute meningoencephalitis with subdural empyema associated with Acanthamoeba in an immunocompetent individual. J R Coll Physicians Edinb 2025; 55 (3): 184-187. doi: 10.1177/14782715251342120.  30.&amp;nbsp; &amp;nbsp; Mätz-Rensing K, Kunze M, Zöller M, Roos C, Kiderlen AF, Ludwig C, Kaup FJ. Fatal Balamuthia mandrillaris infection in a gorilla - first case of balamuthiasis in Germany. J Med Primatol 2011; 40 (6): 437-440. doi: 10.1111/j.1600-0684.2011.00479.x.  31.&amp;nbsp; &amp;nbsp; Balczun C, Scheid PL. Detection of Balamuthia mandrillaris DNA in the storage case of contact lenses in Germany. Parasitol Res 2016; 115 (5): 2111-2114. doi: 10.1007/s00436-016-4979-4.  32.&amp;nbsp; &amp;nbsp; Bernhard-Nocht-Institut für Tropenmedizin (BNITM).  https://www.bnitm.de/labordiagnostik/service/nationales-referenzzentrum  
  &amp;nbsp; &amp;nbsp;  
       
  &amp;nbsp;  
                ]]>
            </content>

                            <updated>2026-02-16T09:00:00+01:00</updated>
                    </entry>

    
    
        <entry>
            <title type="text">Ausgabe 6.2025 | Zeitschrift für Infektionstherapie</title>
            <id>https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/ausgabe-6.2025-zeitschrift-fuer-infektionstherapie</id>
            <link href="https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/ausgabe-6.2025-zeitschrift-fuer-infektionstherapie"/>
            <summary type="html">
                <![CDATA[
                
                                            Hier finden Sie die aktuellen Literaturnachweise der Rubrik &quot;Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie&quot; mit dem Beitrag &quot;West Nil Virus: Ein Virus erobert Deutschland und Europa&quot; sowie die Nachweise aus der Rubrik &quot;Reserveantibiotika im Fokus&quot; mit dem Beitrag ...
                                        ]]>
            </summary>
            <content type="html">
                <![CDATA[
                    Rubrik: Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie     
   West Nil Virus: Ein Virus erobert Deutschland und Europa (S. 58)     
 1.&amp;nbsp; &amp;nbsp; Smithburn KC, Hughes TP, Burke AW, Paul JH. A neurotropic virus isolated from the blood of a native of Uganda. Am J Trop Med 1940; s1-20 (4): 471-492. doi:10.4269/ajtmh.1940.s1-20.471.  2.&amp;nbsp; &amp;nbsp; Nemeth NM, Oesterle PT, Bowen RA. Humoral immunity to West Nile virus is long-lasting and protective in the house sparrow (Passer domesticus). Am J Trop Med Hyg 2009; 80 (5): 864-869. doi: 10.4269/ajtmh.2009.80.864.  3.&amp;nbsp; &amp;nbsp; LaDeau SL, Kilpatrick AM, Marra PP. West Nile virus emergence and large-scale declines of North American bird populations. Nature 2007; 447 (7145): 710-713. doi: 10.1038/nature05829.  4.&amp;nbsp; &amp;nbsp; Bunning ML, Bowen RA, Cropp CB, Sullivan KG, Davis BS, Komar N, Godsey MS, Baker D, Hettler DL, Holmes DA, Biggerstaff BJ, Mitchell CJ. Experimental infection of horses with West Nile virus. Emerg Infect Dis 2002; 8 (4): 380-386. doi: 10.3201/eid0804.010239.  5.&amp;nbsp; &amp;nbsp; Hayes EB, Komar N, Nasci RS, Montgomery SP, O&#039;Leary DR, Campbell GL. Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis 2005; 11 (8): 1167-1173. doi: 10.3201/eid1108.050289a.  6.&amp;nbsp; &amp;nbsp; Campbell GL, Marfin AA, Lanciotti RS, Gubler DJ. West Nile virus. Lancet Infect Dis 2002; 2 (9): 519-29. doi: 10.1016/s1473-3099(02)00368-7.  7.&amp;nbsp; &amp;nbsp; Granwehr BP, Lillibridge KM, Higgs S, Mason PW, Aronson JF, Campbell GA, Barrett AD. West Nile virus: where are we now? Lancet Infect Dis 2004; 4 (9): 547-56. doi: 10.1016/S1473-3099(04)01128-4.  8.&amp;nbsp; &amp;nbsp; Davis LE, DeBiasi R, Goade DE, Haaland KY, Harrington JA, Harnar JB, Pergam SA, King MK, DeMasters BK, Tyler KL. West Nile virus neuroinvasive disease. Ann Neurol 2006; 60 (3): 286-300. doi: 10.1002/ana.20959.  9.&amp;nbsp; &amp;nbsp; Sejvar JJ. Clinical manifestations and outcomes of West Nile virus infection. Viruses 2014; 6 (2): 606-23. doi: 10.3390/v6020606. 10.&amp;nbsp; &amp;nbsp; Cendejas PM, Goodman AG. Vaccination and control methods of West Nile Virus infection in equids and humans. Vaccines (Basel) 2024; 12 (5): 485. doi: 10.3390/vaccines12050485.  11.&amp;nbsp; &amp;nbsp; Martinet JP, Ferté H, Failloux AB, Schaffner F, Depaquit J. Mosquitoes of North-Western Europe as potential vectors of Arboviruses: a review. Viruses. 2019; 11 (11): 1059. doi: 10.3390/v11111059.  12.&amp;nbsp; &amp;nbsp; Giesen C, Herrador Z, Fernandez-Martinez B, Figuerola J, Gangoso L, Vazquez A, Gómez-Barroso D. A systematic review of environmental factors related to WNV circulation in European and Mediterranean countries. One Health 2023; 16: 100478. doi: 10.1016/j.onehlt.2022.100478.  13.&amp;nbsp; &amp;nbsp; Ruiz-López MJ, Aguilera-Sepúlveda P, Cebrián-Camisón S, Figuerola J, Magallanes S, Varona S, Cuesta I, Cano-Gómez C, Sánchez-Mora P, Camacho J, Sánchez-Peña C, Marchena FJ, Ameyugo U, Ruíz S, Sánchez-Seco MP, Agüero M, Jiménez-Clavero MÁ, Fernández-Pinero J, Vázquez A. Re-Emergence of a West Nile Virus (WNV) variant in South Spain with rapid spread capacity. Viruses 2023; 15 (12): 2372. doi: 10.3390/v15122372.  14.&amp;nbsp; &amp;nbsp; Bahuon C, Marcillaud-Pitel C, Bournez L, Leblond A, Beck C, Hars J, Leparc-Goffart I, L&#039;Ambert G, Paty MC, Cavalerie L, Daix C, Tritz P, Durand B, Zientara S, Lecollinet S. West Nile virus epizootics in the Camargue (France) in 2015 and reinforcement of surveillance and control networks. Rev Sci Tech 2016; 35 (3): 811-824. doi: 10.20506/rst.35.3.2571.  15.&amp;nbsp; &amp;nbsp; Pichler V, Giammarioli C, Bellini R, Veronesi R, Arnoldi D, Rizzoli A, Lia RP, Otranto D, Ballardini M, Cobre P, Serini P, Della Torre A, Caputo B. First evidence of pyrethroid resistance in Italian populations of West Nile virus vector Culex pipiens. Med Vet Entomol 2022; 36 (3): 390-395. doi: 10.1111/mve.12573.  16.&amp;nbsp; &amp;nbsp; Balatsos G, Beleri S, Tegos N, Bisia M, Karras V, Zavitsanou E, Papachristos DP, Papadopoulos NT, Michaelakis A, Patsoula E. Overwintering West Nile virus in active Culex pipiens mosquito populations in Greece. Parasit Vectors 2024; 17 (1): 286. doi: 10.1186/s13071-024-06367-6.  17.&amp;nbsp; &amp;nbsp; Cazzin S, Liechti N, Jandrasits D, Flacio E, Beuret C, Engler O, Guidi V. First Detection of West Nile Virus Lineage 2 in Mosquitoes in Switzerland, 2022. Pathogens 2023; 12 (12): 1424. doi: 10.3390/pathogens12121424.  18.&amp;nbsp; &amp;nbsp; Kampen H, Holicki CM, Ziegler U, Groschup MH, Tews BA, Werner D. West Nile Virus Mosquito Vectors (Diptera: Culicidae) in Germany. Viruses 2020 28; 12 (5): 493. doi: 10.3390/v12050493.  19.&amp;nbsp; &amp;nbsp; Kampen H, Tews BA, Werner D. First evidence of West Nile Virus overwintering in mosquitoes in Germany. Viruses. 2021; 13 (12): 2463. doi: 10.3390/v13122463.  20.&amp;nbsp; &amp;nbsp; Rau J, Köchling K, Schäfer M, Tews BA, Wylezich C, Schaub GA, Werner D, Kampen H. Viral RNA in mosquitoes (Diptera: Culicidae) collected between 2019 and 2021 in Germany. Viruses 2023; 15 (12): 2298. doi: 10.3390/v15122298.  21.&amp;nbsp; &amp;nbsp; Ständige Impfkommission Veterinärmedizin (StIKo Vet) am Friedrich-Loeffler-Institut (FLI). Stellungnahme zur Immunisierung von Pferden gegen das West-Nil-Virus.  https://www.openagrar.de/servlets/MCRFileNodeServlet/openagrar_derivate_00017232/Stellungnahme_WNV-Impfung_Pferde_2018-10-22.pdf .  22.&amp;nbsp; &amp;nbsp; Ständige Impfkommission Veterinärmedizin (StIKo Vet) am Friedrich-Loeffler-Institut (FLI). Leitlinie zur Impfung von Pferden. Stand 01.03.2023.  https://www.tieraerzteverband.de/bpt/berufspolitik/leitlinien/dokumente/impfleitlinien/Impfleitlinie-Pferd_2023-03-01.pdf .  23.&amp;nbsp; &amp;nbsp; European Centre for Disease Prevention and Control (ECDC). West Nile virus infection - Annual Epidemiological Report for 2018.  https://www.ecdc.europa.eu/sites/default/files/documents/west-nile-fever-annual-epidemiological-report-2018.pdf .  24.&amp;nbsp; &amp;nbsp; Robert-Koch Institut (RK).  https://survstat.rki.de/Content/Query/Create.aspx .  25.&amp;nbsp; &amp;nbsp; Frank C, Lachmann R. Saison 2024 steckmückenübertragener Krankheitserreger in Deutschland beginnt. Epid Bull 2024; 29: 14-16. doi: 10.25646/12221.  26.&amp;nbsp; &amp;nbsp; Niedersächsisches Landesgesundheitsamt (NLGA). Erster Fall von West-Nil-Fieber bei einem Menschen in Niedersachsen bestätigt.  https://www.nlga.niedersachsen.de/about/pressemitteilungen/erster-fall-von-west-nil-fieber-bei-einem-menschen-in-niedersachsen-bestatigt-235459.html .  27.&amp;nbsp; &amp;nbsp; Rosà R, Marini G, Bolzoni L, Neteler M, Metz M, Delucchi L, Chadwick EA, Balbo L, Mosca A, Giacobini M, Bertolotti L, Rizzoli A. Early warning of West Nile virus mosquito vector: climate and land use models successfully explain phenology and abundance of Culex pipiens mosquitoes in north-western Italy. Parasit Vectors 2014; 7: 269. doi: 10.1186/1756-3305-7-269.  28.&amp;nbsp; &amp;nbsp; Kovach TJ, Kilpatrick AM. Irrigation increases and stabilizes mosquito populations and increases West Nile virus incidence. Sci Rep 2024; 14 (1): 19913. doi: 10.1038/s41598-024-70592-3.  29.&amp;nbsp; &amp;nbsp; Vollans M, Day J, Cant S, Hood J, Kilpatrick AM, Kramer LD, Vaux A, Medlock J, Ward T, Paton RS. Modelling the temperature dependent extrinsic incubation period of West Nile Virus using Bayesian time delay models. J Infect 2024; 89 (6): 106296. doi: 10.1016/j.jinf.2024.106296.  30.&amp;nbsp; &amp;nbsp; Fay RL, Cruz-Loya M, Keyel AC, Price DC, Zink SD, Mordecai EA, Ciota AT. Population-specific thermal responses contribute to regional variability in arbovirus transmission with changing climates. iScience 2024; 27 (6): 109934. doi: 10.1016/j.isci.2024.109934.  31.&amp;nbsp; &amp;nbsp; Paul-Ehrlich-Institut (PEI). Bekanntmachung über die Zulassung von Arzneimitteln - Anordnung von Maßnahmen, die das Risiko der Übertragung einer in Deutschland erworbenen West-Nil-Virus (WNV)-Infektion durch Blutkomponenten zur Transfusion (zelluläre Blutzubereitungen und therapeutische Frischplasmen) und durch Stammzellzubereitungen zur hämatopoetischen Rekonstitution minimieren können. 18.93.2020.  https://www.pei.de/SharedDocs/Downloads/DE/newsroom/bundesanzeiger/veroeffentlichungen/2020/banz-at-04-06-2020-b6.html.   32.&amp;nbsp; &amp;nbsp; Faddy HM, Osiowy C, Custer B, Busch M, Stramer SL, Adesina O, van de Laar T, Tsoi WC, Styles C, Kiely P, Margaritis A, Kwon SY, Qiu Y, Deng X, Lewin A, Jørgensen SW, Erikstrup C, Juhl D, Sauleda S, Camacho Rodriguez BA, Coral LJCS, Gaviria García PA, Oota S, O&#039;Brien SF, Wendel S, Castro E, Navarro Pérez L, Harvala H, Davison K, Reynolds C, Jarvis L, Grabarczyk P, Kopacz A, Łętowska M, O&#039;Flaherty N, Young F, Williams P, Burke L, Chua SS, Muylaert A, Page I, Jones A, Niederhauser C, Vermeulen M, Laperche S, Gallian P, Sawadogo S, Satake M, Gharehbaghian A, Addas-Carvalho M, Blanco S, Gallego SV, Seltsam A, Weber-Schehl M, Al-Riyami AZ, Al Maamari K, Alawi FB, Pandey HC, Mbanya D, França RA, Charlewood R; Virology and Surveillance; Risk Assessment and Policy subgroups of the ISBT Working Party on Transfusion‐transmitted Infectious Diseases. International review of blood donation nucleic acid amplification testing. Vox Sang 2024; 119 (4): 315-325. doi: 10.1111/vox.13592.  33.&amp;nbsp; &amp;nbsp; European Centre for Disease Prevention and Control (ECDC). Surveillance, prevention and control of West Nile virus and Usutu virus infections in the EU/EEA.  https://www.ecdc.europa.eu/sites/default/files/documents/Surveillance_prevention_and_control_of_WNV_and_Usutu_virus_infections_in_the_EU-EEA.pdf . 
 &amp;nbsp; 
    Rubrik: Reserveantibiotika im Fokus    
   Meropenem/Vaborbactam: aktuelle Daten zu Wirksamkeit und Sicherheit des Reserveantibiotikums (S. 59)    
  1.&amp;nbsp; &amp;nbsp; Fachinformation Vaborem (Meropenem/Vaborbactam). Berlin-Chemie. Stand 07/2023. URL:  https://www.medical-hub.berlin-chemie.de/sites/g/files/fugoka451/files/products/documents/147730_vaborem_fi-0723.pdf  [09.09.2025]&amp;nbsp; &amp;nbsp;&amp;nbsp;  2.&amp;nbsp; &amp;nbsp; U.S. Food &amp;amp; Drug Administration (FDA). VABOMERE (meropenem and vaborbactam): Full Prescribing Information. Dec 2024. URL:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209776s009lbl.pdf  [09.09.2025]&amp;nbsp; &amp;nbsp;&amp;nbsp;  3.&amp;nbsp; &amp;nbsp; Kaye, K.S. et al. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. JAMA 2018; 319(8):788-799. doi: 10.1001/jama.2018.0438  4.&amp;nbsp; &amp;nbsp; Wunderink, R.G. et al. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. Infect Dis Ther 2018; 7(4):439-455. doi: 10.1007/s40121-018-0214-1  5.&amp;nbsp; &amp;nbsp; European Medicines Agency (EMA). Assessment report Vabomere (Meropenem/Vaborbactam). Stand 20.09.2018. URL:  https://www.ema.europa.eu/en/documents/assessment-report/vabomere-epar-public-assessment-report_en.pdf  [09.09.2025]  6.&amp;nbsp; &amp;nbsp; Jin, D. et al. Real-world effectiveness and safety of meropenem-vaborbactam in the treatment of carbapenem-resistant enterobacterales (CRE) infections: a systematic review and meta-analysis. J Chemother 2025; published online Feb 13, 2025. doi: 10.1080/1120009X.2025.2465129  7.&amp;nbsp; &amp;nbsp; Tiseo, G. et al. Real-world experience with meropenem/vaborbactam for the treatment of infections caused by ESBL-producing Enterobacterales and carbapenem-resistant Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis 2024; published online Feb 20, 2024. doi: 10.1007/s10096-024-04758-2  8.&amp;nbsp; &amp;nbsp; Tumbarello, M. et al. Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study. JAC Antimicrob Resist 2022; 4(1):dlac022. doi: 10.1093/jacamr/dlac022  9.&amp;nbsp; &amp;nbsp; Tumbarello, M. et al. Outcomes and Predictors of Mortality in Patients With KPC-Kp Infections Treated With Meropenem Vaborbactam: An Observational Multicenter Study. Open Forum Infect Dis 2024; 11(6):ofae273. doi: 10.1093/ofid/ofae273  10.&amp;nbsp; &amp;nbsp; Ackley, R. et al. Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother 2020; 64(5):e02313-19. doi: 10.1128/AAC.02313-19.  11.&amp;nbsp; &amp;nbsp; Alosaimy, S. et al. Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa. Open Forum Infect Dis 2021; 8(8):ofab371. doi: 10.1093/ofid/ofab371  12.&amp;nbsp; &amp;nbsp; Shields, R.K. et al. Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections. Clin Infect Dis 2020; 71(3):667-671. doi: 10.1093/cid/ciz1131&amp;nbsp;  13.&amp;nbsp; &amp;nbsp; Marino A, Maraolo AE, Mazzitelli M et al. Head-to-head: meropenem/vaborbactam versus ceftazidime/avibactam in ICUs patients with KPC-producing K. pneumoniae infections– results from a retrospective multicentre study. Infection 2025; published online Jul 16, 2025. doi: 10.1007/s15010-025-02608-7  14.&amp;nbsp; &amp;nbsp; Tamma PD, Heil EL, Justo JA, et al. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis 2024; published online Aug 7, 2024. doi: 10.1093/cid/ciae403  15.&amp;nbsp; &amp;nbsp; Paul, M. et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect 2022; 28(4): 521-547. doi: 10.1016/j.cmi.2021.11.025&amp;nbsp;   &amp;nbsp;  
  &amp;nbsp;  
       
  &amp;nbsp;  
                ]]>
            </content>

                            <updated>2025-12-15T09:00:00+01:00</updated>
                    </entry>

    
    
        <entry>
            <title type="text">Ausgabe 5.2025 | Zeitschrift für Infektionstherapie</title>
            <id>https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/ausgabe-5.2025-zeitschrift-fuer-infektionstherapie</id>
            <link href="https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/ausgabe-5.2025-zeitschrift-fuer-infektionstherapie"/>
            <summary type="html">
                <![CDATA[
                
                                            Hier finden Sie die aktuellen Literaturnachweise der Rubrik &quot;Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie&quot; mit dem Beitrag &quot;Milzbrand: Gestern so, heute so und morgen vielleicht ganz anders&quot; der Ausgabe 5.2025 der Zeitschrift für Infektionstherapie. 
                                        ]]>
            </summary>
            <content type="html">
                <![CDATA[
                    Rubrik: Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie     
   Milzbrand: Gestern so, heute so und morgen vielleicht ganz anders (S. 46)    
  1.&amp;nbsp; &amp;nbsp; Koch R. Untersuchung über die Aetiologie der Wundinfectionskrankheiten. Leipzig, 1878. Staatsbibliothek zu Berlin – Preußischer Kulturbesitz. SBB-PK, Jx 1782&amp;lt;a&amp;gt; R. urn:nbn:de:kobv:b4-200905193237.  2.&amp;nbsp; &amp;nbsp; Doganay M, Dinc G, Kutmanova A, Baillie L. Human anthrax: update of the diagnosis and treatment. Diagnostics (Basel) 2023; 13 (6): 1056. doi: 10.3390/diagnostics13061056.  3.&amp;nbsp; &amp;nbsp; Friesecke I, Biederbick W, Boecken G, Gottschalk R, Koch HU, Peters G, Peters S, Sasse J, Stich A. Biologische Gefahren II - Entscheidungshilfen zu medizinisch angemessenen Vorgehensweisen in einer B-Gefahrenlage. Herausgeber: Bundesamt für Bevölkerungsschutz und Katastrophenhilfe und Robert Koch Institut (2007).  https://www.rki.de/DE/Content/Infekt/Biosicherheit/Agenzien/bg_anthrax.pdf   4.&amp;nbsp; &amp;nbsp; Guidelines Review Committee der World Health Organization (WHO). Anthrax in humans and animals. 4. Auflage (2008). ISBN: 9789241547536.  5.&amp;nbsp; &amp;nbsp; Hendricks K, Person MK, Bradley JS, Mongkolrattanothai T, Hupert N, Eichacker P, Friedlander AM, Bower WA. Clinical features of patients hospitalized for all routes of anthrax, 1880-2018: A systematic review. Clin Infect Dis 2022; 75 (Suppl 3): S341-S353. doi: 10.1093/cid/ciac534.  6.&amp;nbsp; &amp;nbsp; Robert Koch Institut (RKI).  https://survstat.rki.de/Content/Query/Chart.aspx   7.&amp;nbsp; &amp;nbsp; Kozytska T, Bassiouny M, Chechet O, Ordynska D, Galante D, Neubauer H, Wareth G. Retrospective analysis of official data on Anthrax in Europe with a special reference to Ukraine. Microorganisms 2023; 11 (5): 1294. doi: 10.3390/microorganisms11051294.  8.&amp;nbsp; &amp;nbsp; Meselson M, Guillemin J, Hugh-Jones M, Langmuir A, Popova I, Shelokov A, Yampolskaya O. The Sverdlovsk anthrax outbreak of 1979. Science 1994; 266 (5188): 1202-1208. doi: 10.1126/science.7973702.  9.&amp;nbsp; &amp;nbsp; Jernigan JA, Stephens DS, Ashford DA, Omenaca C, Topiel MS, Galbraith M, Tapper M, Fisk TL, Zaki S, Popovic T, Meyer RF, Quinn CP, Harper SA, Fridkin SK, Sejvar JJ, Shepard CW, McConnell M, Guarner J, Shieh WJ, Malecki JM, Gerberding JL, Hughes JM, Perkins BA; Anthrax Bioterrorism Investigation Team. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001; 7 (6): 933-944. doi: 10.3201/eid0706.010604.  10.&amp;nbsp; &amp;nbsp; Centers for Disease Control and Prevention (CDC).  https://emergency.cdc.gov/agent/agentlist-category.asp   11.&amp;nbsp; &amp;nbsp; Georgopoulos AP, James LM. Anthrax vaccines in the 21st century. Vaccines (Basel) 2024; 12 (2): 159. doi: 10.3390/vaccines12020159.  12.&amp;nbsp; &amp;nbsp; U.S. Food and Drug Administration (FDA).  https://www.fda.gov/vaccines-blood-biologics/vaccines/biothrax   13.&amp;nbsp; &amp;nbsp; Paul-Ehrlich-Institut (PEI).  https://www.pei.de/EN/medicinal-products/vaccines-human/anthrax/anthrax-node.html   14.&amp;nbsp; &amp;nbsp; Berger T, Kassirer M, Aran AA. Injectional anthrax – new presentation of an old disease. Euro Surveill 2014; 19 (32): 20877. doi: 10.2807/1560-7917.es2014.19.32.20877.  15.&amp;nbsp; &amp;nbsp; Zasada AA. Injectional anthrax in human: A new face of the old disease. Adv Clin Exp Med 2018; 27 (4): 553-558. doi: 10.17219/acem/68380.  16.&amp;nbsp; &amp;nbsp; Hanczaruk M, Reischl U, Holzmann T, Frangoulidis D, Wagner DM, Keim PS, Antwerpen MH, Meyer H, Grass G. Injectional anthrax in heroin users, Europe, 2000-2012. Emerg Infect Dis 2014; 20 (2): 322-323. doi: 10.3201/eid2002.120921.  17.&amp;nbsp; &amp;nbsp; Radun D, Bernard H, Altmann M, Schöneberg I, Bochat V, van Treeck U, Rippe RM, Grunow R, Elschner M, Biederbick W, Krause G. Preliminary case report of fatal anthrax in an injecting drug user in North-Rhine-Westphalia, Germany, December 2009. Euro Surveill 2010; 15 (2): 19464. doi: 10.2807/ese.15.02.19464-en.  18.&amp;nbsp; &amp;nbsp; Holzmann T, Frangoulidis D, Simon M, Noll P, Schmoldt S, Hanczaruk M, Grass G, Pregler M, Sing A, Hörmansdorfer S, Bernard H, Grunow R, Zimmermann R, Schneider-Brachert W, Gessner A, Reischl U. Fatal anthrax infection in a heroin user from southern Germany, June 2012. Euro Surveill 2012; 17 (26): 20204. doi: 10.2807/ese.17.26.20204-en.  19.&amp;nbsp; &amp;nbsp; Railean V, Sobolewski J, Jaśkowski JM. Anthrax in one health in Southern and Southeastern Europe – the effect of climate change? Vet Res Commun 2024; 48 (2): 623-632. doi: 10.1007/s11259-023-10238-3.  20.&amp;nbsp; &amp;nbsp; Otieno FT, Gachohi J, Gikuma-Njuru P, Kariuki P, Oyas H, Canfield SA, Bett B, Njenga MK, Blackburn JK. Modeling the potential future distribution of anthrax outbreaks under multiple climate change scenarios for Kenya. Int J Environ Res Public Health 2021; 18 (8): 4176. doi: 10.3390/ijerph18084176.  21.&amp;nbsp; &amp;nbsp; Walsh MG, de Smalen AW, Mor SM. Climatic influence on anthrax suitability in warming northern latitudes. Sci Rep 2018; 8 (1): 9269. doi: 10.1038/s41598-018-27604-w. 
  &amp;nbsp;  
  &amp;nbsp;  
       
  &amp;nbsp;  
                ]]>
            </content>

                            <updated>2025-10-15T09:00:00+02:00</updated>
                    </entry>

    
    
        <entry>
            <title type="text">Ausgabe 3-4.2025 | Zeitschrift für Infektionstherapie</title>
            <id>https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/ausgabe-3-4.2025-zeitschrift-fuer-infektionstherapie</id>
            <link href="https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/ausgabe-3-4.2025-zeitschrift-fuer-infektionstherapie"/>
            <summary type="html">
                <![CDATA[
                
                                            Hier finden Sie die aktuellen Literaturnachweise der Rubrik &quot;Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie&quot; mit den Beiträgen &quot;Nimmt mit 50 Jahren nochmal richtig Fahrt auf: Parvovirus B19&quot; und &quot;Bakterien-Husten nach Virus-Husten: Die Renaissance der Pertussis&quot;, d...
                                        ]]>
            </summary>
            <content type="html">
                <![CDATA[
                    Rubrik: Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie     
   Nimmt mit 50 Jahren nochmal richtig Fahrt auf: Parvovirus B19 (S. 26)    
   1.&amp;nbsp; &amp;nbsp; Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet 1975; 1 (7898): 72-3. doi: 10.1016/s0140-6736(75)91074-0.    2.&amp;nbsp; &amp;nbsp; Yamano H, Nakade T, Ogawa H, Matsukura H, Okubo Y, Yamaguchi H, Okochi K. An unidentified antigen-antibody system, Nakatani, detected by immunoelectro syneresis. Blood Programme 1980; 3: 275-279.    3.&amp;nbsp; &amp;nbsp; Okochi K, Mori R, Miyazaki M, Cohen BJ, Mortimer PP. Nakatani antigen and human parvovirus (B19). Lancet. 1984; 1 (8369): 160-161. doi: 10.1016/s0140-6736(84)90087-4.    4.&amp;nbsp; &amp;nbsp; Reno ML, Cox CR, Powell EA. Parvovirus B19: a clinical and diagnostic review. Clin Microbiol Newsl 2022; 44 (12): 107-114. doi: 10.1016/j.clinmicnews.2022.06.00.    5.&amp;nbsp; &amp;nbsp; Yu MY, Alter HJ, Virata-Theimer ML, Geng Y, Ma L, Schechterly CA, Colvin CA, Luban NL. Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples. Transfusion 2010; 50 (8): 1712-1721. doi: 10.1111/j.1537-2995.2010.02591.x.    6.&amp;nbsp; &amp;nbsp; Arbeitskreis Blut des Bundesministeriums für Gesundheit. Parvovirus B19. Bundesgesundheitsbl 2010, 53: 944-956. doi: 10.1007/s00103-010-1109-9.    7.&amp;nbsp; &amp;nbsp; Farahmand M, Tavakoli A, Ghorbani S, Monavari SH, Kiani SJ, Minaeian S. Molecular and serological markers of human parvovirus B19 infection in blood donors: A systematic review and meta-analysis. Asian J Transfus Sci 2021; 15 (2): 212-222. doi: 10.4103/ajts.ajts_185_20.    8.&amp;nbsp; &amp;nbsp; Röhrer C, Gärtner B, Sauerbrei A, Böhm S, Hottenträger B, Raab U, Thierfelder W, Wutzler P, Modrow S. Seroprevalence of parvovirus B19 in the German population. Epidemiol Infect 2008; 136 (11): 1564-1575. doi: 10.1017/S0950268807009958.    9.&amp;nbsp; &amp;nbsp; Reinheimer C, Allwinn R, Doerr HW, Wittek M. Seroepidemiology of parvovirus B19 in the Frankfurt am Main area, Germany: evaluation of risk factors. Infection 2010; 38 (5): 381-385. doi: 10.1007/s15010-010-0035-y.    10.&amp;nbsp; &amp;nbsp; Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev 2002; 15 (3): 485-505. doi: 10.1128/CMR.15.3.485-505.2002&amp;nbsp;    11.&amp;nbsp; &amp;nbsp; Landry ML. Parvovirus B19. Microbiol Spectr 2016; 4 (3). doi: 10.1128/microbiolspec.DMIH2-0008-2015. PMID: 27337440.    12.&amp;nbsp; &amp;nbsp; Bascietto F, Liberati M, Murgano D, Buca D, Iacovelli A, Flacco ME, Manzoli L, Familiari A, Scambia G, D&#039;Antonio F. Outcome of fetuses with congenital parvovirus B19 infection: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2018; 52 (5): 569-576. doi: 10.1002/uog.19092.    13.&amp;nbsp; &amp;nbsp; Beck R, Exler S, Enders M. Parvovirus B19-Infektion und Schwangerschaft. Epid Bull 2024; 24: 3-7. doi: 10.25646/12157.    14.&amp;nbsp; &amp;nbsp; Robert Koch Institut (RKI).  https://survstat.rki.de/Content/Query/Create.aspx     15.&amp;nbsp; &amp;nbsp; European Center for Disease and Control (ECDC). Increase in parvovirus B19 detections – multi-country – 2024. Wkly Bull 16. 14.-20.04.2024.  https://www.ecdc.europa.eu/sites/default/files/documents/communicable-disease-threats-report-week-16-2024_final.pdf     16.&amp;nbsp; &amp;nbsp; &amp;nbsp;European Center for Disease and Control (ECDC). Risks posed by reported increased circulation of human parvovirus B19 in the EU/EEA. Threat Assessment Brief. 05.06.2024.  https://www.ecdc.europa.eu/en/publications-data/risks-posed-reported-increased-circulation-human-parvovirus-b19-eueea     17.&amp;nbsp; &amp;nbsp; d&#039;Humières C, Fouillet A, Verdurme L, Lakoussan SB, Gallien Y, Coignard C, Hervo M, Ebel A, Soares A, Visseaux B, Maire B, Juan PH, Parent du Châtelet I, Guthmann JP, Durand J. An unusual outbreak of parvovirus B19 infections, France, 2023 to 2024. Euro Surveill 2024; 29 (25): 2400339. doi: 10.2807/1560-7917.ES.2024.29.25.2400339.    18.&amp;nbsp; &amp;nbsp; Nordholm AC, Trier Møller F, Fischer Ravn S, Flink Sørensen L, Moltke-Prehn A, Elskær Mollerup J, Funk T, Sperling L, Jeyaratnam U, Træholt Franck K, Hjort-Pedersen K, Hjørnet Kamper C, Thoft Nielsen R, Jokelainen P, Wessman M. Epidemic of parvovirus B19 and disease severity in pregnant people, Denmark, January to March 2024. Euro Surveill 2024; 29 (24): 2400299. doi: 10.2807/1560-7917.ES.2024.29.24.2400299.    19.&amp;nbsp; &amp;nbsp; Patalon T, Saciuk Y, Trotzky D, Pachys G, Ben-Tov A, Segal Y, Gazit S. An Outbreak of Parvovirus B19 in Israel. Viruses 2023; 15 (11): 2261. doi: 10.3390/v15112261.    20.&amp;nbsp; &amp;nbsp; Fourgeaud J, Allali S, Toubiana J, Pinhas Y, Frange P, Leruez-Ville M, Cohen JF. Post-COVID-19 pandemic outbreak of severe Parvovirus B19 primary infections in Paris, France: 10-year interrupted time-series analysis (2012-2023). J Clin Virol 2023; 167: 105576. doi: 10.1016/j.jcv.2023.105576.    21.&amp;nbsp; &amp;nbsp; Guillet M, Bas A, Lacoste M, Ricard C, Visse C, Barlet V, Malard L, Le Cam S, Morel P, de Lamballerie X, Laperche S, Gallian P. New atypical epidemiological profile of parvovirus B19 revealed by molecular screening of blood donations, France, winter 2023/24. Euro Surveill 2024; 29 (21): 2400253. doi: 10.2807/1560-7917.ES.2024.29.21.2400253.    22.&amp;nbsp; &amp;nbsp; Russcher A, van Boven M, Benincà E, Verweij EJTJ, Molenaar-de Backer MWA, Zaaijer HL, Vossen ACTM, Kroes ACM. Changing epidemiology of parvovirus B19 in the Netherlands since 1990, including its re-emergence after the COVID-19 pandemic. Sci Rep 2024; 14 (1): 9630. doi: 10.1038/s41598-024-59582-7.    23.&amp;nbsp; &amp;nbsp; Drews SJ, Charlton C, O&#039;Brien SF, Burugu S, Denomme GA. Decreasing parvovirus B19 and hepatitis A nucleic acid test positivity rates in Canadian plasma donors following the initiation of COVID-19 restriction in March 2020. Vox Sang 2024; 119 (6): 624-629. doi: 10.1111/vox.13616.    24.&amp;nbsp; &amp;nbsp; Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (AWMF). Labordiagnostik schwangerschaftsrelevanter Virusinfektionen: S2k-Leitlinie Registernummer 093/001.  https://register.awmf.org/assets/guidelines/093-001l_S2k_Labordiagnostik-schwangerschaftsrelevanter-Virusinfektionen_2022-02.pdf     25.&amp;nbsp; &amp;nbsp;  https://www.labor-enders.de/konsiliarlabor-parvoviren/   
  &amp;nbsp;  
   Bakterien-Husten nach Virus-Husten: Die Renaissance der Pertussis&amp;nbsp;(S. 26)   
      1.&amp;nbsp; &amp;nbsp; Gordon JE, Hood RI. Whooping cough and its epidemiological anomalies. Am J Med Sci 1951; 222 (3): 333-361. doi: 10.1097/00000441-195109000-00011.    2.&amp;nbsp; &amp;nbsp; Zatovkaňuková P, Slíva J. The potential dangers of whooping cough: a case of rib fracture and pneumothorax. BMC Infect Dis 2024; 24 (1): 1293. doi: 10.1186/s12879-024-10192-8.  3.&amp;nbsp; &amp;nbsp; Robert-Koch Institut (RKI).  https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Pertussis.html   4.&amp;nbsp; &amp;nbsp; Bordet JJBV, Gengou OPV. Le Microbe de la coqueluche. An Inst Pasteur 1906; 20: 731-741.  5.&amp;nbsp; &amp;nbsp; Gregg KA, Merkel TJ. Pertussis Toxin: A Key Component in Pertussis Vaccines? Toxins (Basel) 2019; 11 (10): 557. doi: 10.3390/toxins11100557.  6.&amp;nbsp; &amp;nbsp; Goldsmith JA, Nguyen AW, Wilen RE, Wijagkanalan W, McLellan JS, Maynard JA. Structural basis for antibody neutralization of pertussis toxin. bioRxiv 2024 Sep 23:2024.09.23.614357. doi: 10.1101/2024.09.23.614357.&amp;nbsp;  7.&amp;nbsp; &amp;nbsp; Hellenbrand W, Wichmann O, Liese J, Heininger U, Wirsing v König CH, Riffelmann M, Terhardt M, Fink E, Kümmel C, Schöneberger K, Schroeder S: Workshop Bericht – Drei Jahre bundesweite Keuchhusten-Meldepflicht: Erfahrungsaustausch zwischen ÖGD, Ärzteschaft und beteiligten Laboren zur Identifizierung von Maßnahmen zur Verbesserung der Surveillance. Epid Bull 2017; 21: 187-197. doi: 10.17886/EpiBull-2017-029.  8.&amp;nbsp; &amp;nbsp; Perkins TA, Tran QM. Timing is everything when it comes to pertussis vaccination. Lancet Infect Dis 2022; 22 (2): 158-159. doi: 10.1016/S1473-3099(21)00353-4.  9.&amp;nbsp; &amp;nbsp; Ständige Impfkommission. Empfehlungen der Ständigen Impfkommission (STIKO) beim Robert Koch-Institut 2024. Epid Bull 2024; 4: 1-72 doi: 10.25646/11892.4.  10.&amp;nbsp; &amp;nbsp; Eidgenössischen Kommission für Impffragen.  https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/allgemeine-empfehlungen/schweizerischer-impfplan.pdf.download.pdf/schweizerischer-impfplan-de.pdf .  11.&amp;nbsp; &amp;nbsp; Nationales Impfgremium Österreich.  https://www.sozialministerium.at/impfplan .  12.&amp;nbsp; &amp;nbsp; Robert-Koch Institut (RKI).  https://survstat.rki.de/Content/Query/Create.aspx .  13.&amp;nbsp; &amp;nbsp; Bagcchi S. Pertussis cases rise in Denmark. Lancet Infect Dis 2023; 23 (11): e469. doi: 10.1016/S1473-3099(23)00645-X.  14.&amp;nbsp; &amp;nbsp; Venkatesan P. Whooping cough cases rising. Lancet Respir Med 2024; 12 (8) :e50. doi: 10.1016/S2213-2600(24)00204-2.  15.&amp;nbsp; &amp;nbsp; Wise J. Whooping cough: What&#039;s behind the rise in cases and deaths in England? BMJ 2024; 385: q1118. doi: 10.1136/bmj.q1118.  16.&amp;nbsp; &amp;nbsp; Holt E. Pertussis outbreak in Czech Republic. Lancet Infect Dis 2024; 24 (6): e359. doi: 10.1016/S1473-3099(24)00291-3.  17.&amp;nbsp; &amp;nbsp; Hu Y, Guo M, Yao K. Infections in preschool and school-aged children are driving the recent rise in pertussis in China. J Infect 2024; 88 (6): 106170. doi: 10.1016/j.jinf.2024.106170.  18.&amp;nbsp; &amp;nbsp; Tanne JH. Whooping cough: Fivefold rise in US cases spells return to pre-pandemic levels. BMJ 2024; 386: q2114. doi: 10.1136/bmj.q2114.  19.&amp;nbsp; &amp;nbsp; Statista GmbH.  https://de.statista.com/statistik/daten/studie/77595/umfrage/impfquote-gegen-diphtherie-tetanus-und-pertussis-bei-kindern-in-deutschland/   20.&amp;nbsp; &amp;nbsp; Witte J, Zeitler A, Diekmanshemke, Hasemann L. DAK-Kinder- und Jugendreport 2022.  https://www.dak.de/dak/download/dak-kinder--und-jugendreport-2022-pdf-2584960.pd f.  21.&amp;nbsp; &amp;nbsp; Böhmer MM, Hellenbrand W, Matysiak-Klose D, Heininger U, Müters S, Wichmann O. Pertussis vaccination coverage among adults in Germany. Dtsch Med Wochenschr. 2013; 138 (28-29): 1451-1457. doi: 10.1055/s-0033-1343249.  22.&amp;nbsp; &amp;nbsp; Hohlbaum K. Pertussis: Viel zu niedrige Impfquoten bei Erwachsenen. Dtsch Arztebl 2013; 110 (38): A-1710 / B-1514 / C-1490.  23.&amp;nbsp; &amp;nbsp; Saxena K, Marden JR, Carias C, Bhatti A, Patterson-Lomba O, Gomez-Lievano A, Yao L, Chen YT. Impact of the COVID-19 pandemic on adolescent vaccinations: projected time to reverse deficits in routine adolescent vaccination in the United States. Curr Med Res Opin 2021; 37 (12): 2077-2087. doi: 10.1080/03007995.2021.1981842.  24.&amp;nbsp; &amp;nbsp; Saitoh A, Okabe N. Changes and remaining challenges for the Japanese immunization program: Closing the vaccine gap. Vaccine 2021; 39 (22): 3018-3024. doi: 10.1016/j.vaccine.2021.04.023.  25.&amp;nbsp; &amp;nbsp; Prasad N, Turner N, Alexander S. Early childhood education staff are falling through a vaccination policy gap in New Zealand. N Z Med J 2022; 135 (1548): 96-102.  26.&amp;nbsp; &amp;nbsp; Evans B, Keiser O, Kaiser L, Jombart T. Analysis of global routine immunisation coverage shows disruption and stagnation during the first two-years of the COVID-19 pandemic with tentative recovery in 2022. Vaccine X 2023; 15: 100383. doi: 10.1016/j.jvacx.2023.100383.  27.&amp;nbsp; &amp;nbsp; Cohen R, Ashman M, Taha MK, Varon E, Angoulvant F, Levy C, Rybak A, Ouldali N, Guiso N, Grimprel E. Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap? Infect Dis Now 2021; 51 (5): 418-423. doi: 10.1016/j.idnow.2021.05.004.  28.&amp;nbsp; &amp;nbsp; McIntyre PB, Best E, Byrnes CA, Sinclair O, Trenholme A, Grant CC. Pertussis deaths in New Zealand without community transmission-an infant immunity gap? Lancet Reg Health West Pac 2023; 37: 100850. doi: 10.1016/j.lanwpc.2023.100850.  29.&amp;nbsp; &amp;nbsp; Martinón-Torres F, Heininger U, Thomson A, Wirsing von König CH. Controlling pertussis: how can we do it? A focus on immunization. Expert Rev Vaccines 2018; 17 (4): 289-297. doi: 10.1080/14760584.2018.1445530.&amp;nbsp;  30.&amp;nbsp; &amp;nbsp; Schielke A, Takla A, von Kries R, Wichmann O, Hellenbrand W. Marked Underreporting of Pertussis Requiring Hospitalization in Infants as Estimated by Capture-Recapture Methodology, Germany, 2013-2015. Pediatr Infect Dis J 2018; 37 (2): 119-125. doi: 10.1097/INF.0000000000001698.  31.&amp;nbsp; &amp;nbsp; MacIntyre CR, de Sousa JC, Heininger U, Kardos P, Konstantopoulos A, Middleton D, Nolan T, Papi A, Rendon A, Rizzo A, Sampson K, Sette A, Sobczyk E, Tan T, Weil-Olivier C, Weinberger B, Wilkinson T, von König CHW. Public health management of pertussis in adults: Practical challenges and future strategies. Hum Vaccin Immunother 2024; 20 (1): 2377904. doi: 10.1080/21645515.2024.2377904.  32.&amp;nbsp; &amp;nbsp; Guiso N, Wirsing von König CH. Surveillance of pertussis: methods and implementation. Expert Rev Anti Infect Ther 2016; 14 (7): 657-667. doi: 10.1080/14787210.2016.1190272.  33.&amp;nbsp; &amp;nbsp; Bethke N, Gellert P, Knoll N, Weber N, Seybold J. A school-based educational on-site vaccination intervention for adolescents in an urban area in Germany: feasibility and psychometric properties of instruments in a pilot study. BMC Public Health 2022; 22 (1): 60. doi: 10.1186/s12889-021-12443-8.  34.&amp;nbsp; &amp;nbsp; Pluijmaekers AJM, Steens A, Houweling H, Rots NY, Benschop KSM, van Binnendijk RS, Bodewes R, Brouwer JGM, Buisman A, Duizer E, van Els CACM, Hament JM, den Hartog G, Kaaijk P, Kerkhof K, King AJ, van der Klis FRM, Korthals Altes H, van der Maas NAT, van Meijeren DL, Middeldorp M, Rijnbende-Geraerts SD, Sanders EAM, Veldhuijzen IK, Vlaanderen E, Voordouw ACG, Vos ERA, de Wit J, Woudenberg T, van Vliet JA, de Melker HE. A literature review and evidence-based evaluation of the Dutch national immunisation schedule yield possibilities for improvements. Vaccine X. 2024; 20: 100556. doi: 10.1016/j.jvacx.2024.100556.  35.&amp;nbsp; &amp;nbsp; Galeas-Pena M, Hirsch A, Kuang E, Hoffmann J, Gellings P, Brown JB, Limbert VM, Callahan CL, McLachlan JB, Morici LA. A novel outer membrane vesicle adjuvant improves vaccine protection against Bordetella pertussis. NPJ Vaccines. 2024; 9 (1): 190. doi: 10.1038/s41541-024-00990-1.  36.&amp;nbsp; &amp;nbsp; Tan C, Xiao Y, Chen S, Liu T, Zhou J, Zhang S, Hu Y, Zhou J, She Z, Tian B, Wu A, Li C. Bibliometrics analysis and knowledge mapping of pertussis vaccine research: trends from 1994 to 2023. Infection. 2024; 53 (3): 1001-1012. doi: 10.1007/s15010-024-02414-7.&amp;nbsp;  37.&amp;nbsp; &amp;nbsp; Monterrubio-López GP, Llamas-Monroy JL, Martínez-Gómez ÁA, Delgadillo-Gutiérrez K. Novel vaccine candidates of Bordetella pertussis identified by reverse vaccinology. Biologicals 2024; 85: 101740. doi: 10.1016/j.biologicals.2023.101740.  38.&amp;nbsp; &amp;nbsp; Ernst K. Novel strategies to inhibit Pertussis toxin. Toxins (Basel) 2022; 14 (3): 187. doi: 10.3390/toxins14030187.  39.&amp;nbsp; &amp;nbsp; Lietz S, Sommer A, Sokolowski LM, Kling C, Rodriguez Alfonso AA, Preising N, Alpízar-Pedraza D, King J, Streit L, Schröppel B, van Erp R, Barth E, Schneider M, Münch J, Michaelis J, Ständker L, Wiese S, Barth H, Pulliainen AT, Scanlon K, Ernst K. Alpha-1 antitrypsin inhibits pertussis toxin. J Biol Chem 2024; 300 (12): 107950. doi: 10.1016/j.jbc.2024.107950.  40.&amp;nbsp; &amp;nbsp; Pyles GM, Huckaby AB, Gutierrez MdlP, Witt WT, Mateu-Borrás M, Dublin SR, Rocuskie-Marker C, Sesti BN, Peasak K, Bitzer GJ, Rader N, Weaver KL, Boehm DT, Fitzgerald N, Chapman J, Ulicny S, Damron FH, Barbier M. Virus-like particles displaying the mature C-terminal domain of filamentous hemagglutinin are immunogenic and protective against Bordetella pertussis respiratory infection in mice. Infect Immun 2024; 92 (8): e0027024. doi: 10.1128/iai.00270-24.   
  &amp;nbsp;  
    Rubrik:&amp;nbsp;Antimikrobielle Resistenzen    
   Globale Entwicklung antimikrobieller Resistenzen – ein Update&amp;nbsp;(S. 28)     1.&amp;nbsp; &amp;nbsp; Murray, Christopher J L et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022; 399(10325): 629 – 655. doi: 10.1016/S0140-6736(21)02724-0    2.&amp;nbsp; &amp;nbsp; Naghavi, Mohsen et al. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. Lancet 2024; 404(10459): 1199 – 1226. doi: 10.1016/S0140-6736(24)01867-1    3.&amp;nbsp; &amp;nbsp; World Health Organization (WHO). WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. published online May 17, 2024.  https://iris.who.int/bitstream/handle/10665/376776/9789240093461-eng.pdf?sequence=1  [11.03.2025]    4.&amp;nbsp; &amp;nbsp; Robert Koch Institut (RKI). Staphylokokken-Erkrankungen, insbesondere Infektionen durch MRSA. RKI-Ratgeber. Stand 17.01.2025. https:// www.rki.de/DE/Aktuelles/Publikationen/RKI-Ratgeber/Ratgeber/Ratgeber_Staphylokokken_MRSA.html?nn=16906848#doc16804810bodyText14  [11.03.2025]    5.&amp;nbsp; &amp;nbsp; World Health Organization (WHO). Estimating the impact of vaccines in reducing antimicrobial resistance and antibiotic use. published online Oct 10, 2024.  https://iris.who.int/bitstream/handle/10665/379116/9789240098787-eng.pdf?sequence=1  [12.03.2025]    6.&amp;nbsp; &amp;nbsp; Chaw, Pa Saidou et al. Knowledge, attitude and practice of Gambian health practitioners towards antibiotic prescribing and microbiological testing: a cross-sectional survey. Trans R Soc Trop Med Hyg 2017; 111(3):117-124. doi: 10.1093/trstmh/trx027&amp;nbsp;     
    Rubrik:&amp;nbsp;Chikungunya-Virus    
   Chikungunya – neue Präventionsmöglichkeiten durch aktive Immunisierung&amp;nbsp;(S. 31)   
  &amp;nbsp; 1.&amp;nbsp; &amp;nbsp; European Centre for Disease Prevention and Control (ECDC). Chikungunya virus disease.  https://www.ecdc.europa.eu/en/chikungunya-virus-disease  [03.06.2025]  2.&amp;nbsp; &amp;nbsp; Liu, Q et al. Chikungunya virus in Europe: A retrospective epidemiology study from 2007 to 2023. PLoS Negl Trop Dis 2025; 19(3):e0012904. doi: 10.1371/journal.pntd.0012904  3.&amp;nbsp; &amp;nbsp; Tiozzo, G et al. Assessing chikungunya’s economic burden and impact on health-related quality of life: Two systematic literature reviews. PLoS Negl Trop Dis 19(5): e0012990. doi: 10.1371/journal.pntd.0012990  4.&amp;nbsp; &amp;nbsp; Tavares, WG et al. Chikungunya fever in hospitalized children and adolescents: clinical and epidemiological aspects in a region of northeastern Brazil. J Pediatr (Rio J) 2025;101(3):466-472. doi: 10.1016/j.jped.2025.01.010  5.&amp;nbsp; &amp;nbsp; Micheleto, JPC et al. Risk factors for mortality in patients with chikungunya: A systematic review and meta-analysis. Trop Med Int Health 2025; 30(4): 235-245. doi: 10.1111/tmi.14088  6.&amp;nbsp; &amp;nbsp; European Centre for Disease Prevention and Control (ECDC). Chikungunya worldwide overview - Situation update, March 2025.  https://www.ecdc.europa.eu/en/chikungunya-monthly  [03.06.2025]  7.&amp;nbsp; &amp;nbsp; Schneider, M et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2023; 401(10394): 2138–2147. doi: 10.1016/S0140-6736(23)00641-4  8.&amp;nbsp; &amp;nbsp; Ixchiq – Zusammenfassung der Merkmale des Arzneimittels, Stand 23.05.2025.  https://www.ema.europa.eu/de/documents/product-information/ixchiq-epar-product-information_de.pdf&amp;nbsp;   9.&amp;nbsp; &amp;nbsp; Rote-Hand-Brief: Ixchiq (Chikungunya-Impfstoff): Neue Kontraindikation bei Patienten ab 65 Jahren, während die EU-weite Überprüfung läuft. Stand 22.05.2025.  https://www.pei.de/SharedDocs/Downloads/DE/newsroom/veroeffentlichungen-arzneimittel/rhb/25-05-22-rhb-ixchiq-chikungunya-impfstoff.pdf?__blob=publicationFile&amp;amp;v=2#:~:text=Ixchiq%20ist%20seit%20dem%2028,abgeschwächtes%20CHIKV%20des%20Stamms%20Δ5nsP3.   10.&amp;nbsp; &amp;nbsp; European Medicines Agency (EMA). EMA starts review of Ixchiq (live attenuated chikungunya vaccine). published online May 7, 2025.  https://www.ema.europa.eu/en/news/ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine  [04.06.2025]  11.&amp;nbsp; &amp;nbsp; U.S. Food &amp;amp; Drug Administration (FDA). FDA and CDC Recommend Pause in Use of Ixchiq (Chikungunya Vaccine, Live) in Individuals 60 Years of Age and Older While Postmarketing Safety Reports are Investigated. published online May 9, 2025.  https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-and-cdc-recommend-pause-use-ixchiq-chikungunya-vaccine-live-individuals-60-years-age-and-older  [07.06.2025]  12.&amp;nbsp; &amp;nbsp; Buerger, V et al. Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents. Lancet Infect Dis 2025; 25(1): 114–125. doi: 10.1016/S1473-3099(24)00458-4  13.&amp;nbsp; &amp;nbsp; Vimkunya – Zusammenfassung der Merkmale des Arzneimittels, Stand 24.03.2025.  https://www.ema.europa.eu/de/documents/product-information/vimkunya-epar-product-information_de.pdf &amp;nbsp;  14.&amp;nbsp; &amp;nbsp; Richardson, JS et al. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2025; 405(10487):1343-1352. doi: 10.1016/S0140-6736(25)00345-9  15.&amp;nbsp; &amp;nbsp; Bachmann, MF et al. Virus-like particles: a versatile and effective vaccine platform. Expert Rev Vaccines 2025; 24(1): 444-456. doi: 10.1080/14760584.2025.2508517  16.&amp;nbsp; &amp;nbsp; Tindale, LC et al. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2025; 405(10487):1353-1361. doi: 10.1016/S0140- 6736(25)00372-1    
  &amp;nbsp;  
  &amp;nbsp;  
       
  &amp;nbsp;  
                ]]>
            </content>

                            <updated>2025-07-15T09:00:00+02:00</updated>
                    </entry>

    
    
        <entry>
            <title type="text">Ausgabe 2.2025 | Zeitschrift für Infektionstherapie</title>
            <id>https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/ausgabe-2.2025-zeitschrift-fuer-infektionstherapie</id>
            <link href="https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/ausgabe-2.2025-zeitschrift-fuer-infektionstherapie"/>
            <summary type="html">
                <![CDATA[
                
                                            Hier finden Sie die aktuellen Literaturnachweise der Rubrik &quot;Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie&quot; mit dem Beitrag &quot;Eine Mykoplasmen-Welle schwappt über Deutschland und Europa&quot; der Ausgabe 2.2025 der Zeitschrift für Infektionstherapie. 
                                        ]]>
            </summary>
            <content type="html">
                <![CDATA[
                   Rubrik: Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie    
   Eine Mykoplasmen-Welle schwappt über Deutschland und Europa&amp;nbsp;(S. 14)     
 1.&amp;nbsp;&amp;nbsp;&amp;nbsp; Chaudhry R, Ghosh A, Chandolia A. Pathogenesis of Mycoplasma pneumoniae: An update. Indian J Med Microbiol 2016; 34 (1): 7-16. doi: 10.4103/0255-0857.174112.  2.&amp;nbsp;&amp;nbsp;&amp;nbsp; Taylor-Robinson D. Infections due to species of Mycoplasma and Ureaplasma: an update. Clin Infect Dis 1996; 23 (4): 671-682. doi: 10.1093/clinids/23.4.671.  3.&amp;nbsp;&amp;nbsp;&amp;nbsp; Uphoff CC, Drexler HG. Eradication of Mycoplasma contaminations from cell cultures. Curr Protoc Mol Biol 2014; 106: 28.5.1-28.5.12. doi: 10.1002/0471142727.mb2805s106.  4.&amp;nbsp;&amp;nbsp;&amp;nbsp; Qiu Y, Mao S, Li X, Chen Y, Chen W, Wen Y, Liu P. Chinese advances in understanding and managing genitourinary tract infections caused by Mycoplasma genitalium, Mycoplasma hominis, and Ureaplasma urealyticum. Arch Microbiol 2024; 207 (1): 5. doi: 10.1007/s00203-024-04204-z.  5.&amp;nbsp;&amp;nbsp;&amp;nbsp; Beeton ML, Zhang XS, Uldum SA, Bébéar C, Dumke R, Gullsby K, Ieven M, Loens K, Nir-Paz R, Pereyre S, Spiller OB, Chalker VJ; ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC) Mycoplasma pneumoniae subgroup; ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC) Mycoplasma pneumoniae subgroup members not listed as an individual author. Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016. Euro Surveill 2020; 25 (2): 1900112. doi: 10.2807/1560-7917.ES.2020.25.2.1900112.  6.&amp;nbsp;&amp;nbsp;&amp;nbsp; Suttorp N, Welte T, Marre R, Stenger S, Pletz M, Rupp J, Schütte H, Rohde G; CAPNETZ-Studiengruppe. CAPNETZ. The competence network for community-acquired pneumonia (CAP). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2016; 59 (4): 475-481. German. doi: 10.1007/s00103-016-2318-7.  7.&amp;nbsp;&amp;nbsp;&amp;nbsp; Dumke R, Schnee C, Pletz MW, Rupp J, Jacobs E, Sachse K, Rohde G; Capnetz Study Group. Mycoplasma pneumoniae and Chlamydia spp. infection in community-acquired pneumonia, Germany, 2011-2012. Emerg Infect Dis 2015; 21 (3): 426-434. doi: 10.3201/eid2103.140927.  8.&amp;nbsp;&amp;nbsp;&amp;nbsp; Wetzke M, Schütz K, Kopp MV, Seidenberg J, Vogelberg C, Ankermann T, Happle C, Voigt G, Köster H, Illig T, Lex C, Schuster A, Maier R, Panning M, Barten G, Rohde G, Welte T, Hansen G. Pathogen spectra in hospitalised and nonhospitalised children with community-acquired pneumonia. ERJ Open Res 2023; 9 (2): 00286-2022. doi: 10.1183/23120541.00286-2022.  9.&amp;nbsp;&amp;nbsp;&amp;nbsp; Daxboeck F, Krause R, Wenisch C. Laboratory diagnosis of Mycoplasma pneumoniae infection. Clin Microbiol Infect 2003; 9 (4): 263-73. doi: 10.1046/j.1469-0691.2003.00590.x. 10.&amp;nbsp;&amp;nbsp;&amp;nbsp; Li W, Liu Y, Zhao Y, Tao R, Li Y, Shang S. Rapid diagnosis of Mycoplasma pneumoniae in children with pneumonia by an immuno-chromatographic antigen assay. Sci Rep 2015; 5: 15539. doi: 10.1038/srep15539.  11.&amp;nbsp;&amp;nbsp;&amp;nbsp; Meyer Sauteur PM, Unger WWJ, van Rossum AMC, Berger C. The art and science of diagnosing Mycoplasma pneumoniae infection. Pediatr Infect Dis J 2018; 37 (11): 1192-1195. doi: 10.1097/INF.0000000000002171.  12.&amp;nbsp;&amp;nbsp;&amp;nbsp; Gao L, Sun Y. Laboratory diagnosis and treatment of Mycoplasma pneumoniae infection in children: a review. Ann Med 2024; 56 (1): 2386636. doi: 10.1080/07853890.2024.2386636.  13.&amp;nbsp;&amp;nbsp;&amp;nbsp; Gesellschaft für Pädiatrische Pneumologie (GPP) und der Deutschen Gesellschaft für Pädiatrische Infektiologie (DGPI). Management der ambulant erworbenen Pneumonie bei Kindern und Jugendlichen (paediatric community-acquired pneumonia, pCAP). AWMF-2Sk-Leitlinie Registernummer 048-013&amp;nbsp; (Stand 01/2024; Gültigkeit bis 01/2029).  14.&amp;nbsp;&amp;nbsp;&amp;nbsp; Meyer Sauteur PM, Seiler M, Trück J, Unger WWJ, Paioni P, Relly C, Staubli G, Haas T, Gysin C, M Bachmann L, van Rossum AMC, Berger C. Diagnosis of Mycoplasma pneumoniae pneumonia with measurement of specific antibody-secreting cells. Am J Respir Crit Care Med 2019; 200 (8): 1066-1069. doi: 10.1164/rccm.201904-0860LE.  15.&amp;nbsp;&amp;nbsp;&amp;nbsp; Meyer Sauteur PM, Trück J, van Rossum AMC, Berger C. Circulating antibody-secreting cell response during Mycoplasma pneumoniae childhood pneumonia. J Infect Dis 2020; 222 (1): 136-147. doi: 10.1093/infdis/jiaa062.  16.&amp;nbsp;&amp;nbsp;&amp;nbsp; Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin (DGP), Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG), Deutsche Gesellschaft für Infektiologie (DGI), Deutsche Gesellschaft für Internistische Intensivmedizin und Notfallmedizin (DGIIN), Gesellschaft für Virologie (GfV), Kompetenznetzwerk CAPNETZ, Deutsche Gesellschaft für Allgemeinmedizin (DEGAM), Deutsche Gesellschaft für Geriatrie (DGG), Deutsche Gesellschaft für Palliativmedizin (DGP), Österreichische Gesellschaft für Pneumologie (ÖGP), Österreichische Gesellschaft für Infektionskrankheiten und Tropenmedizin (ÖGIT), Schweizerische Gesellschaft für Pneumologie (SGP), und Schweizerische Gesellschaft für Infektiologie (SGInf). Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie – Update 2021. AWMF-S3-Leilinie Registernummer 020-020 (Stand 04/2021; Gültigkeit bis 04/2025).  17.&amp;nbsp;&amp;nbsp;&amp;nbsp; Ramaloko WT, Maningi NE, Osei Sekyere J. Global prevalence, resistance rates, and underlying resistance mechanisms of clinical Mycoplasma and Ureaplasma species. J Appl Microbiol 2025; 136 (1): lxae308. doi: 10.1093/jambio/lxae308.  18.&amp;nbsp;&amp;nbsp;&amp;nbsp; European Centre for Disease Prevention and Control (ECDC). Increase in respiratory infections due to Mycoplasma pneumoniae in the EU/EEA during the season 2023/204. Communicable Disease Threats Report. Week 48. 2. Dezember 2023.  https://www.ecdc.europa.eu/sites/default/files/documents/communicable-disease-threats-report-week-48-2023_0.pdf .  19.&amp;nbsp;&amp;nbsp;&amp;nbsp; UK Health Security Agency. Mycoplasma pneumoniae surveillance in England and Wales, January 2019 to March 2024.  https://www.gov.uk/government/publications/mycoplasma-pneumoniae-surveillance-january-2019-to-march-2024/mycoplasma-pneumoniae-surveillance-in-england-and-wales-january-2019-to-march-2024 .  20.&amp;nbsp;&amp;nbsp;&amp;nbsp; Bolluyt DC, Euser SM, Souverein D, van Rossum AM, Kalpoe J, van Westreenen M, Goeijenbier M, Snijders D, Eggink D, Jongenotter F, van Lelyveld SF, van Houten MA. Increased incidence of Mycoplasma pneumoniae infections and hospital admissions in the Netherlands, November to December 2023. Euro Surveill 2024; 29 (4): 2300724. doi: 10.2807/1560-7917.ES.2024.29.4.2300724.  21.&amp;nbsp;&amp;nbsp;&amp;nbsp; Nordholm AC, Søborg B, Jokelainen P, Lauenborg Møller K, Flink Sørensen L, Grove Krause T, Anker Uldum S, Emborg HD. Mycoplasma pneumoniae epidemic in Denmark, October to December, 2023. Euro Surveill 2024; 29 (2): 2300707. doi: 10.2807/1560-7917.ES.2024.29.2.2300707.  22.&amp;nbsp;&amp;nbsp;&amp;nbsp; Raghuram A, Furmanek S, Chandler T, Rashid S, Mattingly W, Ramirez J. Description of a Current Outbreak of Mycoplasma pneumoniae in the United States. Pathogens 2025; 14 (1): 60. doi: 10.3390/pathogens14010060.  23.&amp;nbsp;&amp;nbsp;&amp;nbsp; Landesuntersuchungsanstalt für das Gesundheits- und Veterinärwesen (LUA). Jahresberichte für Infektionskrankheiten im Freistaat Sachsen.  https://www.lua.sachsen.de/lua-jahresberichte-4103.html .   24.&amp;nbsp;&amp;nbsp;&amp;nbsp; Dumke R. The high-incidence period of Mycoplasma pneumoniae infections 2023/2024 in southeast Germany was associated with a low level of macrolide resistance. Infection 2024; 52 (6): 2525-2527. doi: 10.1007/s15010-024-02336-4.  25.&amp;nbsp;&amp;nbsp;&amp;nbsp; Meyer Sauteur PM, Beeton ML, Uldum SA, Bossuyt N, Vermeulen M, Loens K, Pereyre S, Bébéar C, Keše D, Day J, Afshar B, Chalker VJ, Greub G, Nir-Paz R, Dumke R; ESGMAC–MyCOVID Study Team. Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021. Euro Surveill 2022; 27 (19): 2100746. doi: 10.2807/1560-7917.ES.2022.27.19.2100746.  26.&amp;nbsp;&amp;nbsp;&amp;nbsp; Meyer Sauteur PM, Beeton ML; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycoplasma and Chlamydia Infections (ESGMAC), and the ESGMAC Mycoplasma pneumoniae Surveillance (MAPS) study group. Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions. Lancet Microbe 2024; 5 (2): e100-e101. doi: 10.1016/S2666-5247(23)00344-0.  27.&amp;nbsp;&amp;nbsp;&amp;nbsp; Guo Y, Yang D, Cao Y, Ding X, Chen L, Huo B, Li Y. Influence of COVID-19 public health restrictions on community-acquired pneumonia pathogens in children in Henan, China: a multicenter retrospective study. BMC Infect Dis 2024; 24 (1): 1381. doi: 10.1186/s12879-024-10268-5.  28.&amp;nbsp;&amp;nbsp;&amp;nbsp; Liu P, Xu M, Lu L, Zhu X, Jia R, Dong N, Su L, Xu J. Resurgence of common respiratory viruses and mycoplasma pneumoniae after ending the zero-COVID policy in Shanghai. Sci Rep 2025; 15 (1): 1765. doi: 10.1038/s41598-025-85852-z.  
 &amp;nbsp; 
 &amp;nbsp; 
     
 &amp;nbsp; 
                ]]>
            </content>

                            <updated>2025-04-15T09:00:00+02:00</updated>
                    </entry>

    
    
        <entry>
            <title type="text">Ausgabe 1.2025 | Zeitschrift für Infektionstherapie</title>
            <id>https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/ausgabe-1.2025-zeitschrift-fuer-infektionstherapie</id>
            <link href="https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/ausgabe-1.2025-zeitschrift-fuer-infektionstherapie"/>
            <summary type="html">
                <![CDATA[
                
                                            Hier finden Sie die aktuellen Literaturnachweise der Rubrik &quot;Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie&quot; mit dem Beitrag &quot;Good night. Sleep tight. Don&#039;t let the bedbugs bite.&quot; der Ausgabe 1.2025 der Zeitschrift für Infektionstherapie. 
                                        ]]>
            </summary>
            <content type="html">
                <![CDATA[
                   Rubrik: Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie    
   Good night. Sleep tight. Don&#039;t let the bedbugs bite.&amp;nbsp;(S. 2)     
  1.&amp;nbsp;&amp;nbsp;&amp;nbsp; Leung AKC, Lam JM, Barankin B, Leong KF, Hon KL. Bed bug infestation: an updated review. Curr Pediatr Rev 2024; 20 (2): 137-149. doi: 10.2174/1573396320666230406084801.  2.&amp;nbsp;&amp;nbsp;&amp;nbsp; Thomas C, Castillo Valladares H, Berger TG, Chang AY. Scabies, bedbug, and body lice infestations: A review. JAMA. 2024; 332(14):1189-1199. doi: 10.1001/jama.2024.13896.  3.&amp;nbsp;&amp;nbsp;&amp;nbsp; Akhoundi M, Chebbah D, Elissa N, Brun S, Jan J, Lacaze I, Izri A. Volatile Organic Compounds: A Promising Tool for Bed Bug Detection. Int J Environ Res Public Health 2023; 20 (6): 5214. doi: 10.3390/ijerph20065214  4.&amp;nbsp;&amp;nbsp;&amp;nbsp; Knudsen JT, Ignell R. Semiochemicals modulating bed bug behaviour. Curr Opin Insect Sci 2024; 64: 101207. doi: 10.1016/j.cois.2024.101207.  5.&amp;nbsp;&amp;nbsp;&amp;nbsp; Hamlili FZ, Bérenger JM, Parola P. Cimicids of Medical and Veterinary Importance. Insects 2023; 14 (4): 392. doi: 10.3390/insects14040392.  6.&amp;nbsp;&amp;nbsp;&amp;nbsp; Aak A, Rukke BA, Soleng A, Rosnes MK. Questing activity in bed bug populations: male and female responses to host signals. Physiol Entomol 2014; 39 (3):199-207. doi: 10.1111/phen.12062.  7.&amp;nbsp;&amp;nbsp;&amp;nbsp; Goddard J, de Shazo R. Psychological effects of bed bug attacks (Cimex lectularius L.). Am J Med 2012; 125 (1): 101-103. doi: 10.1016/j.amjmed.2011.08.010.  8.&amp;nbsp;&amp;nbsp;&amp;nbsp; Burrows S, Perron S, Susser S. Suicide following an infestation of bed bugs. Am J Case Rep 2013; 14: 176-178. doi: 10.12659/AJCR.883926.  9.&amp;nbsp;&amp;nbsp;&amp;nbsp; Delaunay P, Blanc V, Del Giudice P, Levy-Bencheton A, Chosidow O, Marty P, Brouqui P. Bedbugs and infectious diseases. Clin Infect Dis 2011; 52 (2): 200-210. doi: 10.1093/cid/ciq102.  10.&amp;nbsp;&amp;nbsp;&amp;nbsp; El Hamzaoui B, Laroche M, Bechah Y, Bérenger JM, Parola P. Testing the Competence of Cimex lectularius Bed Bugs for the Transmission of Borrelia recurrentis, the Agent of Relapsing Fever. Am J Trop Med Hyg 2019; 100 (6): 1407-1412. doi: 10.4269/ajtmh.18-0804.  11.&amp;nbsp;&amp;nbsp;&amp;nbsp; Akhoundi M, Zumelzu C, Sereno D, Marteau A, Brun S, Jan J, Izri A. Bed Bugs (Hemiptera, Cimicidae): A Global challenge for public health and control kanagement. Diagnostics (Basel) 2023; 13 (13): 2281. doi: 10.3390/diagnostics13132281.  12.&amp;nbsp;&amp;nbsp;&amp;nbsp; Crawley SE, Borden JH. Detection and monitoring of bed bugs (Hemiptera: Cimicidae): review of the underlying science, existing products and future prospects. Pest Manag Sci 2021; 77 (12): 5334-5346. doi: 10.1002/ps.6574.  13.&amp;nbsp;&amp;nbsp;&amp;nbsp; Doggett SL, Lee CY. Historical and contemporary control options against bed bugs, Cimex spp. Annu Rev Entomol 2023; 68: 169-190. doi: 10.1146/annurev-ento-120220-015010.  14.&amp;nbsp;&amp;nbsp;&amp;nbsp; Moshaverinia A, Raouf-Rahmati A, Jarahi L, Bergquist R, Zorrilla-Vaca A, Kiani F, Jadidoleslami A, Doggett SL, Zarean M, Majma A, Reza Youssefi M, Moghaddas E, Kiani B. Geographical patterns and mechanisms of Cimex lectularius Linnaeus, 1758, and Cimex hemipterus Fabricius, 1803 (Hemiptera: Cimicidae) resistance to insecticides: a systematic review and meta-analysis. Parasitol Res 2022; 121 (7): 1817-1827. doi: 10.1007/s00436-022-07530-7.  15.&amp;nbsp;&amp;nbsp;&amp;nbsp; Tagesschau online. Bettwanzen-Alarm in Frankreich. Beitrag vom 04.10.2023.  https://www.tagesschau.de/ausland/europa/frankreich-bettwanzen-100.html   16.&amp;nbsp;&amp;nbsp;&amp;nbsp; Spiegel online. „Keiner ist sicher“: Frankreich hat vor Olympia ein Bettwanzen-Problem. Beitrag vom 29.09.2023.  https://www.spiegel.de/panorama/frankreichs-verkehrsminister-stellt-sich-bettwanzen-problem-a-4c5a51f3-bd0e-46b0-b447-cdf4cdb47783   17.&amp;nbsp;&amp;nbsp;&amp;nbsp; Tagesschau online. Paris wirft Moskau „Bettwanzen-Panikmache“ vor. Beitrag vom 01.03.2024.  https://www.tagesschau.de/ausland/europa/frankreich-russland-bettwanzen-diplomatie-100.html   18.&amp;nbsp;&amp;nbsp;&amp;nbsp; Spiegel online. Russland soll Bettwanzen-Hysterie über soziale Medien verstärkt haben. Beitrag vom 17.03.2024.  https://www.spiegel.de/ausland/frankreich-russland-soll-bettwanzen-hysterie-ueber-soziale-medien-verstaerkt-haben-a-282137ac-6988-45be-be40-d06e11be60d4   19.&amp;nbsp;&amp;nbsp;&amp;nbsp; Krüger A, Vander Pan A. Bettwanzen wandern mit.  https://www.umweltbundesamt.de/sites/default/files/medien/1410/publikationen/uba_flyer_bettwanzen_screen_einzelseiten.pdf   
 &amp;nbsp; 
 &amp;nbsp; 
 &amp;nbsp; 
     
 &amp;nbsp; 
                ]]>
            </content>

                            <updated>2025-02-17T09:00:00+01:00</updated>
                    </entry>

    
    
        <entry>
            <title type="text">Ausgabe 6.2024 | Zeitschrift für Infektionstherapie</title>
            <id>https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/ausgabe-6.2024-zeitschrift-fuer-infektionstherapie</id>
            <link href="https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/ausgabe-6.2024-zeitschrift-fuer-infektionstherapie"/>
            <summary type="html">
                <![CDATA[
                
                                            Hier finden Sie die aktuellen Literaturnachweise der Rubrik &quot;Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie&quot; mit dem Beitrag &quot;Großer Hund – großes Problem, kleiner Hund – großes Problem&quot; der Ausgabe 6.2024 der Zeitschrift für Infektionstherapie. 
                                        ]]>
            </summary>
            <content type="html">
                <![CDATA[
                   Rubrik: Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie    
   Großer Hund – großes Problem, kleiner Hund – großes Problem&amp;nbsp;(S. 62)     
   1.&amp;nbsp;&amp;nbsp;&amp;nbsp; Erasmus D. Erasmi Roterodami Familiarivm Colloqviorvm Opvs. Coloniae Agrippinae Horst 1578.      2.&amp;nbsp;&amp;nbsp;&amp;nbsp;  https://de.statista.com/statistik/daten/studie/181167/umfrage/haustier-anzahl-hunde-im-haushalt/     3.&amp;nbsp;&amp;nbsp;&amp;nbsp; Rothe K, Tsokos M, Handrick W. Animal and human bite wounds. Dtsch Arztebl Int 2015; 112: 433-442; quiz 443. doi: 10.3238/arztebl.2015.0433.    4.&amp;nbsp;&amp;nbsp;&amp;nbsp;  https://de.statista.com/statistik/daten/studie/157643/umfrage/todesfaelle-durch-hundebisse-nach-bundeslaendern/     5.&amp;nbsp;&amp;nbsp;&amp;nbsp; Brenner DJ, Hollis DG, Fanning GR, Weaver RE. Capnocytophaga canimorsus sp. nov. (formerly CDC group DF-2), a cause of septicemia following dog bite, and C. cynodegmi sp. nov., a cause of localized wound infection following dog bite. J Clin Microbiol 1989; 27: 231-235. doi: 10.1128/jcm.27.2.231-235.1989.    6.&amp;nbsp;&amp;nbsp;&amp;nbsp; Mally M, Paroz C, Shin H, Meyer S, Soussoula LV, Schmiediger U, Saillen-Paroz C, Cornelis GR. Prevalence of Capnocytophaga canimorsus in dogs and occurrence of potential virulence factors. Microbes Infect 2009; 11: 509-514. doi: 10.1016/j.micinf.2009.02.005.    7.&amp;nbsp;&amp;nbsp;&amp;nbsp; van Dam AP, van Weert A, Harmanus C, Hovius KE, Claas EC, Reubsaet FA. Molecular characterization of Capnocytophaga canimorsus and other canine Capnocytophaga spp. and assessment by PCR of their frequencies in dogs. J Clin Microbiol 2009; 47: 3218-3225. doi: 10.1128/JCM.01246-09.    8.&amp;nbsp;&amp;nbsp;&amp;nbsp; Hess E, Renzi F, Koudad D, Dol M, Cornelis GR. Identification of virulent Capnocytophaga canimorsus isolates by capsular typing. J Clin Microbiol 2017; 55: 1902-1914. doi: 10.1128/JCM.00249-17.    9.&amp;nbsp;&amp;nbsp;&amp;nbsp; H. Shin, M. Mally, M. Kuhn, C. Paroz, G. R. Cornelis: Escape from immune surveillance by Capnocytophaga canimorsus. In: J Infect Dis. 195, 2007, S. 375–386.    10.&amp;nbsp;&amp;nbsp;&amp;nbsp; S. Meyer, H. Shin, G. R. Cornelis: Capnocytophaga canimorsus resists phagocytosis by macrophages and blocks the ability of macrophages to kill other bacteria. In: Immunobiology. 213(9-10), 2008, S. 805–814.    11.&amp;nbsp;&amp;nbsp;&amp;nbsp; M. Mally, H. Shin, C. Paroz, R. Landmann, G. R. Cornelis: Capnocytophaga canimorsus: A Human Pathogen Feeding at the Surface of Epithelial Cells and Phagocytes. In: PLoS Pathogens. 4(9), 2008, S. e1000164. doi:10.1371/journal.ppat.1000164.    12.&amp;nbsp;&amp;nbsp;&amp;nbsp; Killington K, Lee N, Asher R, Farrant O, Stone N. Purpura fulminans secondary to Capnocytophaga canimorsus bacteraemia following a dog bite: A case report and review of literature. Access Microbiol 2023; 5: acmi000505.v3. doi: 10.1099/acmi.0.000505.v3.    13.&amp;nbsp;&amp;nbsp;&amp;nbsp; Taniyama D, Imoto K, Suzuki M, Imaoka K. A case of uncomplicated bacteremia caused by Capnocytophaga canimorsus in an immunocompetent patient. Cureus 2023; 15: e44293. doi: 10.7759/cureus.44293.    14.&amp;nbsp;&amp;nbsp;&amp;nbsp; Kondo N, Matsumura Y, Sugiyama T, Miyahara M, Imamura A, Kasahara Y, Nagashima H, Hanaoka N, Fujiyoshi N, Inaba S. Fatal case of Capnocytophaga sepsis from a dog bite in a patient with splenic hypoplasia. Acute Med Surg 2023; 10: e849. doi: 10.1002/ams2.849.    15.&amp;nbsp;&amp;nbsp;&amp;nbsp; Parisi X, Pihán G. Purpura fulminans due to Capnocytophaga canimorsus. Br J Haematol 2023; 202: 455. doi: 10.1111/bjh.18837.    16.&amp;nbsp;&amp;nbsp;&amp;nbsp; Peeters M, Pelzer J, Yazar O, Salemans P, Wong C, Decraemer G, Bouwman L. Fatal sepsis with peripheral necrosis due to Capnocytophagus canimorsus infection after dog bite: a case report. Ann Med Surg (Lond) 2023; 85: 982-985. doi: 10.1097/MS9.0000000000000280.    17.&amp;nbsp;&amp;nbsp;&amp;nbsp; Fernández Vecilla D, Angulo López I, Calvo Muro FE, Aspichueta Vivanco C, Renzi F, Pereda Martínez ME, Rosselló Soria J, Díaz de Tuesta Del Arco JL. Fatal septic shock and Waterhouse-Friderichsen syndrome caused by serovar B Capnocytophaga canimorsus in an immunocompetent patient. Case report and review. Rev Esp Quimioter 2023; 36: 92-96. doi: 10.37201/req/060.2022.    18.&amp;nbsp;&amp;nbsp;&amp;nbsp; Salazar Rodríguez DJ, Plata Ciézar AJ, Gaitán Román D, Urbano Carrillo CA. The dog, valves&#039; best friend: infective endocarditis due to Capnocytophaga canimorsus-a case report. Eur Heart J Case Rep 2023; 7: ytad228. doi: 10.1093/ehjcr/ytad228.    19.&amp;nbsp;&amp;nbsp;&amp;nbsp; González Sans D, Carratalà Marín P, Guillen-Del-Castillo A. Infective endocarditis due to Capnocytophaga canimorsus in an immunocompetent patient. Med Clin (Barc) 2023; 160: 463-464. doi: 10.1016/j.medcli.2023.01.014.    20.&amp;nbsp;&amp;nbsp;&amp;nbsp; Hino C, Veltman J. Capnocytophaga tricuspid valve endocarditis: a case report and literature review. Access Microbiol 2022; 4: acmi000355. doi: 10.1099/acmi.0.000355.    21.&amp;nbsp;&amp;nbsp;&amp;nbsp; O&#039;Dwyer M, Houlihan JA, O&#039;Rourke S, Young V, O&#039;Connell B. An infected bicuspid aortic valve, an anomalous coronary artery, and a dog-bitten postman. J Investig Med High Impact Case Rep 2022; 10: 23247096221092283. doi: 10.1177/23247096221092283.    22.&amp;nbsp;&amp;nbsp;&amp;nbsp; Le Breton C, El Braidy B, Durup F, Garot J. Bobo-Newton acute myocarditis caused by Capnocytophaga canimorsus: a case report. Eur Heart J Case Rep 2023; 7: ytad209. doi: 10.1093/ehjcr/ytad209.    23.&amp;nbsp;&amp;nbsp;&amp;nbsp; Lam JH, Horvath R, Amodeo M. Culture-negative Capnocytophaga canimorsus meningitis diagnosed by 16s ribosomal RNA polymerase chain reaction in an immunocompetent veterinarian and a review of the literature. Intern Med J 2023; 53: 1054-1057. doi: 10.1111/imj.16110.    24.&amp;nbsp;&amp;nbsp;&amp;nbsp; Fennell AG, Wilson KS, Caja KR, Parikh PM. Capnocytophaga canimorsus meningitis in a 38-year-old immunocompetent woman from household pet exposure. Am J Emerg Med 2022; 56: 396.e1-396.e3. doi: 10.1016/j.ajem.2022.03.043.    25.&amp;nbsp;&amp;nbsp;&amp;nbsp; López Martínez D, Hermida Pérez B, Santos Seoane MS, García González P. Bacterial peritonitis secondary to Capnocytophaga canimorsus. Rev Esp Enferm Dig 2024; 116(4):228-229. doi: 10.17235/reed.2023.9571/2023.     26.&amp;nbsp;&amp;nbsp;&amp;nbsp; Vanwielendaele M, Chérif MY, Hing M, Colman M, Ferchichi MA, Raoul JF, Maillart E, Badot V, Clevenbergh P. Hematogenous septic arthritis of a non-prosthetic shoulder caused by Capnocytophaga canimorsus: A case report and review of the literature. IDCases 2023; 31: e01717. doi: 10.1016/j.idcr.2023.e01717.    27.&amp;nbsp;&amp;nbsp;&amp;nbsp; Fernández Vecilla D, Aspichueta Vivanco C, Angulo López I, Baraia-Etxaburu Artetxe JM, Renzi F, Díaz de Tuesta Del Arco JL. A case of septic arthritis caused by Capnocytophaga canimorsus in an HIV patient. Access Microbiol 2022; 4: acmi000368. doi: 10.1099/acmi.0.000368.    28.&amp;nbsp;&amp;nbsp;&amp;nbsp; Trainor-Moss S, Acquah RR, Peirse M, Beadles W. Renal abscess with Capnocytophaga canimorsus infection from a dog bite. BMJ Case Rep 2022; 15: e250447. doi: 10.1136/bcr-2022-250447.    29.&amp;nbsp;&amp;nbsp;&amp;nbsp; Schuler F, Padberg JS, Hullermann C, Kümpers P, Lepper J, Schulte M, Uekötter A, Schaumburg F, Kahl BC. Lethal Waterhouse-Friderichsen syndrome caused by Capnocytophaga canimorsus in an asplenic patient. BMC Infect Dis 2022; 22: 696. doi: 10.1186/s12879-022-07590-1.    30.&amp;nbsp;&amp;nbsp;&amp;nbsp; Meyer EC, Alt-Epping S, Moerer O, Büttner B. Fatal septic shock due to Capnocytophaga canimorsus bacteremia masquerading as COVID-19 pneumonia - a case report. BMC Infect Dis 2021; 21: 736. doi: 10.1186/s12879-021-06422-y.    31.&amp;nbsp;&amp;nbsp;&amp;nbsp; Wendt R, Schauff C, Lübbert C. An asplenic with life-threatening Capnocytophaga canimorsus sepsis. IDCases 2020; 21: e00828. doi: 10.1016/j.idcr.2020.e00828.    32.&amp;nbsp;&amp;nbsp;&amp;nbsp; Mader N, Lührs F, Herget-Rosenthal S, Langenbeck M. Being licked by a dog can be fatal: Capnocytophaga canimorsus sepsis with purpura fulminans in an immunocompetent man. Eur J Case Rep Intern Med 2019; 6: 001268.doi: 10.12890/2019_001268.    33.&amp;nbsp;&amp;nbsp;&amp;nbsp; Hundertmark M, Williams T, Vogel A, Moritz M, Bramlage P, Pagonas N, Ritter O, Sasko B. Capnocytophaga canimorsus as cause of fatal sepsis. Case Rep Infect Dis 2019; 2019: 3537507. doi: 10.1155/2019/3537507.    34.&amp;nbsp;&amp;nbsp;&amp;nbsp; Markewitz RDH, Graf T. Capnocytophaga canimorsus infection. N Engl J Med 2020; 383: 1167. doi: 10.1056/NJMicm1916407.    35.&amp;nbsp;&amp;nbsp;&amp;nbsp; Pohle M, Kunze R, Prüller R. Fallbericht: Infektion mit Capnocygtophaga canimorsus nach einem Hundebiss. Epidem Bull 2006; 24: 186-187. ISSN 1430-0265.   
 &amp;nbsp; 
 &amp;nbsp; 
     
 &amp;nbsp; 
                ]]>
            </content>

                            <updated>2024-12-17T09:00:00+01:00</updated>
                    </entry>

    
    
        <entry>
            <title type="text">Ausgabe 5.2024 | Zeitschrift für Infektionstherapie</title>
            <id>https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/ausgabe-5.2024-zeitschrift-fuer-infektionstherapie</id>
            <link href="https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/ausgabe-5.2024-zeitschrift-fuer-infektionstherapie"/>
            <summary type="html">
                <![CDATA[
                
                                            Hier finden Sie die aktuellen Literaturnachweise der Rubrik &quot;Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie&quot; mit dem Beitrag &quot;Wenn einem schon die Zecken das Steak beim BBQ verleiden&quot; der Ausgabe 5.2024 der Zeitschrift für Infektionstherapie. 
                                        ]]>
            </summary>
            <content type="html">
                <![CDATA[
                   Rubrik: Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie    
   Wenn einem schon die Zecken das Steak beim BBQ verleiden (S. 48)    
  1.&amp;nbsp;&amp;nbsp;&amp;nbsp; Kahl O, Gray JS. The biology of Ixodes ricinus with emphasis on its ecology. Ticks Tick Borne Dis 2023; 14: 102114. doi: 10.1016/j.ttbdis.2022.102114.  2.&amp;nbsp;&amp;nbsp;&amp;nbsp; Steinbrink A, Brugger K, Margos G, Kraiczy P, Klimpel S. The evolving story of Borrelia burgdorferi sensu lato transmission in Europe. Parasitol Res 2022; 121: 781-803. doi: 10.1007/s00436-022-07445-3.  3.&amp;nbsp;&amp;nbsp;&amp;nbsp; Enkelmann J, Böhmer M, Fingerle V, Siffczyk C, Werber D, Littmann M, Merbecks SS, Helmeke C, Schroeder S, Hell S, Schlotthauer U, Burckhardt F, Stark K, Schielke A, Wilking H. Incidence of notified Lyme borreliosis in Germany, 2013-2017. Sci Rep 2018; 8: 14976. doi: 10.1038/s41598-018-33136-0.  4.&amp;nbsp;&amp;nbsp;&amp;nbsp; Brestrich G, Hagemann C, Diesing J, Kossack N, Stark JH, Pilz A, Angulo FJ, Yu H, Suess J. Incidence of Lyme Borreliosis in Germany: A retrospective observational healthcare claims study. Ticks Tick Borne Dis 2024; 15: 102326. doi: 10.1016/j.ttbdis.2024.102326.  5.&amp;nbsp;&amp;nbsp;&amp;nbsp; Zens KD. Tick-Borne Encephalitis - Viral transmission and considerations for vaccination. Ther Umsch 2022; 79: 471-481. doi: 10.1024/0040-5930/a001390.  6.&amp;nbsp;&amp;nbsp;&amp;nbsp; Robert Koch-Institut (RKI): FSME-Risikogebiete in Deutschland (Stand: Januar 2024). Epid Bull 2024; 9: 3-21. doi: 10.25646/11965.  7.&amp;nbsp;&amp;nbsp;&amp;nbsp; Wendt S, Trawinski H, von Braun A, Lübbert C. Durch Zecken übertragbare Erkrankungen. CME 2019; 16: 9-26.  8.&amp;nbsp;&amp;nbsp;&amp;nbsp; Shah T, Li Q, Wang B, Baloch Z, Xia X. Geographical distribution and pathogenesis of ticks and tick-borne viral diseases. Front Microbiol 2023; 14: 1185829. doi: 10.3389/fmicb.2023.1185829.  9.&amp;nbsp;&amp;nbsp;&amp;nbsp; Pienaar R, Neitz AWH, Mans BJ. Tick paralysis: solving an enigma. Vet Sci 2018; 5: 53. doi: 10.3390/vetsci5020053.  10.&amp;nbsp;&amp;nbsp;&amp;nbsp; Simon LV, West B, McKinney WP. Tick paralysis. 2023 Aug 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing 2024. PMID: 29262244.  11.&amp;nbsp;&amp;nbsp;&amp;nbsp; Jeimy S, Zhu R. Tick-borne red meat allergy (α-gal syndrome). CMAJ 2023; 195: E1305-E1306. doi: 10.1503/cmaj.231067.  12.&amp;nbsp;&amp;nbsp;&amp;nbsp; Mollah F, Zacharek MA, Benjamin MR. What is alpha-gal syndrome? JAMA 2024; 331: 86. doi: 10.1001/jama.2023.23097.  13.&amp;nbsp;&amp;nbsp;&amp;nbsp; Wilson JM, Erickson L, Levin M, Ailsworth SM, Commins SP, Platts-Mills TAE. Tick bites, IgE to galactose-alpha-1,3-galactose and urticarial or anaphylactic reactions to mammalian meat: The alpha-gal syndrome. Allergy 2024; 79(6):1440-1454. doi: 10.1111/all.16003.   14.&amp;nbsp;&amp;nbsp;&amp;nbsp; Karim S, Leyva-Castillo JM, Narasimhan S. Tick salivary glycans - a sugar-coated tick bite. Trends Parasitol 2023; 39: 1100-1113. doi: 10.1016/j.pt.2023.09.012.  15.&amp;nbsp;&amp;nbsp;&amp;nbsp; Edlow JA. Alpha-Gal Syndrome: A novel and increasingly common cause of anaphylaxis. Ann Emerg Med 2024; 83(4):380-384. doi: 10.1016/j.annemergmed.2023.08.491.  16.&amp;nbsp;&amp;nbsp;&amp;nbsp; Maldonado-Ruiz LP, Reif KE, Ghosh A, Foré S, Johnson RL, Park Y. High levels of alpha-gal with large variation in the salivary glands of lone star ticks fed on human blood. Sci Rep 2023; 13: 21409. doi: 10.1038/s41598-023-48437-2.  17.&amp;nbsp;&amp;nbsp;&amp;nbsp; Kersh GJ, Salzer J, Jones ES, Binder AM, Armstrong PA, Choudhary SK, Commins GK, Amelio CL, Kato CY, Singleton J, Biggerstaff BJ, Beard CB, Petersen LR, Commins SP. Tick bite as a risk factor for alpha-gal-specific immunoglobulin E antibodies and development of alpha-gal syndrome. Ann Allergy Asthma Immunol 2023; 130: 472-478. doi: 10.1016/j.anai.2022.11.021.  18.&amp;nbsp;&amp;nbsp;&amp;nbsp; Raghavan RK, Peterson AT, Cobos ME, Ganta R, Foley D. Current and Future Distribution of the Lone Star Tick, Amblyomma americanum (L.) (Acari: Ixodidae) in North America. PLoS One 2019; 14: e0209082. doi: 10.1371/journal.pone.0209082.  19.&amp;nbsp;&amp;nbsp;&amp;nbsp; Centers for Disease Control and Prevention (CDC).  https://www.cdc.gov/ticks/geographic_distribution.html   20.&amp;nbsp;&amp;nbsp;&amp;nbsp; Thompson JM, Carpenter A, Kersh GJ, Wachs T, Commins SP, Salzer JS. Geographic Distribution of Suspected Alpha-gal Syndrome Cases - United States, January 2017-December 2022. MMWR Morb Mortal Wkly Rep 2023; 72: 815-820. doi: 10.15585/mmwr.mm7230a2.  21.&amp;nbsp;&amp;nbsp;&amp;nbsp; Biggerstaff BJ, Beard CB, Petersen LR, Kersh GJ, Armstrong PA. Diagnostic testing for galactose-alpha-1,3-galactose, United States, 2010 to 2018. Ann Allergy Asthma Immunol 2021; 126: 411-416.e1. doi: 10.1016/j.anai.2020.12.019.  22.&amp;nbsp;&amp;nbsp;&amp;nbsp; Ailsworth SM, Susi A, Workman LJ, Ji YS, Patel J, Nelson MR, Platts-Mills TAE, Nylund CM, Wilson JM. Alpha-Gal IgE Prevalence Patterns in the United States: An Investigation of 3,000 Military Recruits. J Allergy Clin Immunol Pract 2024; 12: 175-184.e5. doi: 10.1016/j.jaip.2023.10.046.  23.&amp;nbsp;&amp;nbsp;&amp;nbsp; Chitimia-Dobler L, Fachet K, Lindau A, Mackenstedt U, Strube C, Springer A, Eisenberg T, Schaper S, Nava S, Dobler G, Martins TF. Exotic ticks removed from German travelers. Parasitol Res 2024; 123: 120. doi: 10.1007/s00436-024-08144-x.  24.&amp;nbsp;&amp;nbsp;&amp;nbsp; Mihalca AD. Ticks imported to Europe with exotic reptiles. Vet Parasitol 2015; 213: 67-71. doi: 10.1016/j.vetpar.2015.03.024.  25.&amp;nbsp;&amp;nbsp;&amp;nbsp; Hamsten C, Starkhammar M, Tran TA, Johansson M, Bengtsson U, Ahlén G, Sällberg M, Grönlund H, van Hage M. Identification of galactose-α-1,3-galactose in the gastrointestinal tract of the tick Ixodes ricinus; possible relationship with red meat allergy. Allergy 2013; 68: 549-552. doi: 10.1111/all.12128.  26.&amp;nbsp;&amp;nbsp;&amp;nbsp; Statistisches Bundesamt.  https://de.statista.com/statistik/daten/studie/36573/umfrage/pro-kopf-verbrauch-von-fleisch-in-deutschland-seit-2000/   27.&amp;nbsp;&amp;nbsp;&amp;nbsp; Wolver SE, Sun DR, Commins SP, Schwartz LB. A peculiar cause of anaphylaxis: no more steak? The journey to discovery of a newly recognized allergy to galactose-alpha-1,3-galactose found in mammalian meat. J Gen Intern Med 2013; 28: 322-325. doi: 10.1007/s11606-012-2144-z.       
 &amp;nbsp; 
     
 &amp;nbsp; 
                ]]>
            </content>

                            <updated>2024-10-17T09:00:00+02:00</updated>
                    </entry>

    
    
        <entry>
            <title type="text">Ausgabe 3-4.2024 | Zeitschrift für Infektionstherapie</title>
            <id>https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/ausgabe-3-4.2024-zeitschrift-fuer-infektionstherapie</id>
            <link href="https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/ausgabe-3-4.2024-zeitschrift-fuer-infektionstherapie"/>
            <summary type="html">
                <![CDATA[
                
                                            Hier finden Sie die aktuellen Literaturnachweise der Rubriken &quot;Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie&quot; mit den Beiträgen &quot;Vibrio vulnificus – infektiologischer Marker des Klimawandels?&quot; und &quot;Das Auf und Ab der Clostridioides-difficile-Infektion&quot;, sowie der ...
                                        ]]>
            </summary>
            <content type="html">
                <![CDATA[
                   Rubrik: Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie    
    Vibrio vulnificus  – Infektiologischer Marker des Klimawandels?&amp;nbsp;(S.26)    
 1.&amp;nbsp;&amp;nbsp; &amp;nbsp;Farmer 3rd JJ. Vibrio (&quot;Beneckea&quot;) vulnificus, the bacterium associated with sepsis, septicaemia, and the sea. Lancet 1979; 2(8148): 903. doi: 10.1016/s0140-6736(79)92715-6.  2.&amp;nbsp;&amp;nbsp; &amp;nbsp;Baker-Austin C, Oliver JD. Vibrio vulnificus. Trends Microbiol 2020; 28(1): 81-82. doi: 10.1016/j.tim.2019.08.006.  3.&amp;nbsp;&amp;nbsp; &amp;nbsp;Vu TTT, Alter T, Huehn S. Prevalence of Vibrio spp. in retail seafood in Berlin, Germany. J Food Prot 2018; 81(4): 593-597. doi: 10.4315/0362-028X.JFP-17-366.  4.&amp;nbsp;&amp;nbsp; &amp;nbsp;Hartnell RE, Stockley L, Keay W, Rosec JP, Hervio-Heath D, Van den Berg H, Leoni F, Ottaviani D, Henigman U, Denayer S, Serbruyns B, Georgsson F, Krumova-Valcheva G, Gyurova E, Blanco C, Copin S, Strauch E, Wieczorek K, Lopatek M, Britova A, Hardouin G, Lombard B, In&#039;t Veld P, Leclercq A, Baker-Austin C. A pan-European ring trial to validate an international standard for detection of Vibrio cholerae, Vibrio parahaemolyticus and Vibrio vulnificus in seafoods. Int J Food Microbiol 2019; 288: 58-65. doi: 10.1016/j.ijfoodmicro.2018.02.008.  5.&amp;nbsp;&amp;nbsp; &amp;nbsp;International Organization for Standardization (ISO).  https://www.iso.org/standard/74112.html   6.&amp;nbsp;&amp;nbsp; &amp;nbsp;Böer SI, Heinemeyer EA, Luden K, Erler R, Gerdts G, Janssen F, Brennholt N. Temporal and spatial distribution patterns of potentially pathogenic Vibrio spp. at recreational beaches of the German North Sea. Microb Ecol 2013; 65(4): 1052-1067. doi: 10.1007/s00248-013-0221-4.  7.&amp;nbsp;&amp;nbsp; &amp;nbsp;Fleischmann S, Herrig I, Wesp J, Stiedl J, Reifferscheid G, Strauch E, Alter T, Brennholt N. Prevalence and distribution of potentially human pathogenic Vibrio spp. on German North and Baltic Sea coasts. Front Cell Infect Microbiol 2022; 12: 846819. doi: 10.3389/fcimb.2022.846819.  8.&amp;nbsp;&amp;nbsp; &amp;nbsp;Huehn S, Eichhorn C, Urmersbach S, Breidenbach J, Bechlars S, Bier N, Alter T, Bartelt E, Frank C, Oberheitmann B, Gunzer F, Brennholt N, Böer S, Appel B, Dieckmann R, Strauch E. Pathogenic vibrios in environmental, seafood and clinical sources in Germany. Int J Med Microbiol 2014; 304(7): 843-850. doi: 10.1016/j.ijmm.2014.07.010.  9.&amp;nbsp;&amp;nbsp; &amp;nbsp;Kuhnt-Lenz K, Krengel S, Fetscher S, Heer-Sonderhoff A, Solbach W. Sepsis with bullous necrotizing skin lesions due to vibrio vulnificus acquired through recreational activities in the Baltic Sea. Eur J Clin Microbiol Infect Dis 2004; 23(1): 49-52. doi: 10.1007/s10096-003-1056-6.  10.&amp;nbsp;&amp;nbsp; &amp;nbsp;Frank C, Littman M, Alpers K, Hallauer J. Vibrio vulnificus wound infections after contact with the Baltic Sea, Germany. Euro Surveill 2006; 11(8): E060817.1. doi: 10.2807/esw.11.33.03024-en.  11.&amp;nbsp;&amp;nbsp; &amp;nbsp;Brehm TT, Berneking L, Sena Martins M, Dupke S, Jacob D, Drechsel O, Bohnert J, Becker K, Kramer A, Christner M, Aepfelbacher M, Schmiedel S, Rohde H; German Vibrio Study Group. Heatwave-associated Vibrio infections in Germany, 2018 and 2019. Euro Surveill 2021; 26(41): 2002041. doi: 10.2807/1560-7917.ES.2021.26.41.2002041.   12.&amp;nbsp;&amp;nbsp; &amp;nbsp;Meyer HL, Polan C, Burggraf M, Podleska L, Beck P, Steinau HU, Dudda M, Farzaliyev F. &quot;The Baltic Sea Germ&quot;: A case report of necrotizing fasciitis following Vibrio vulnificus infection. Case Rep Orthop 2022; 2022: 5908666. doi: 10.1155/2022/5908666.  13.&amp;nbsp;&amp;nbsp; &amp;nbsp;Bier N, Jäckel C, Dieckmann R, Brennholt N, Böer SI, Strauch E. Virulence profiles of Vibrio vulnificus in German coastal waters, a comparison of North Sea and Baltic Sea isolates. Int J Environ Res Public Health 2015; 12(12): 15943-15959. doi: 10.3390/ijerph121215031. 14.&amp;nbsp;&amp;nbsp; &amp;nbsp;Dupke S, Buchholz U, Fastner J, Förster C, Frank C, Lewin A, Rickerts V, Selinka HC. Impact of climate change on waterborne infections and intoxications. J Health Monit 2023; 8(Suppl 3): 62-77. doi: 10.25646/11402.  15.&amp;nbsp;&amp;nbsp; &amp;nbsp;Meier HEM, Dieterich C, Eilola K, Gröger M, Höglund A, Radtke H, Saraiva S, Wåhlström I. Future projections of record-breaking sea surface temperature and cyanobacteria bloom events in the Baltic Sea. Ambio 2019; 48(11): 1362-1376. doi: 10.1007/s13280-019-01235-5.  16.&amp;nbsp;&amp;nbsp; &amp;nbsp;Schütt EM, Hundsdörfer MAJ, von Hoyningen-Huene AJE, Lange X, Koschmider A, Oppelt N. First steps towards a near real-time modelling system of Vibrio vulnificus in the Baltic Sea. Int J Environ Res Public Health 2023; 20(8): 5543. doi: 10.3390/ijerph20085543.  17.&amp;nbsp;&amp;nbsp; &amp;nbsp;Paz S, Bisharat N, Paz E, Kidar O, Cohen D. Climate change and the emergence of Vibrio vulnificus disease in Israel. Environ Res 2007; 103(3): 390-396. doi: 10.1016/j.envres.2006.07.002.  18.&amp;nbsp;&amp;nbsp; &amp;nbsp;Urquhart EA, Zaitchik BF, Waugh DW, Guikema SD, Del Castillo CE. Uncertainty in model predictions of Vibrio vulnificus response to climate variability and change: a Chesapeake Bay case study. PLoS One 2014; 9(5): e98256. doi: 10.1371/journal.pone.0098256.  19.&amp;nbsp;&amp;nbsp; &amp;nbsp;Baker-Austin C, Trinanes J, Gonzalez-Escalona N, Martinez-Urtaza J. Non-Cholera Vibrios: the microbial barometer of climate change. Trends Microbiol 2017; 25(1): 76-84. doi: 10.1016/j.tim.2016.09.008.  20.&amp;nbsp;&amp;nbsp; &amp;nbsp;Deeb R, Tufford D, Scott GI, Moore JG, Dow K. Impact of climate change on Vibrio vulnificus abundance and exposure risk. Estuaries Coast 2018; 41(8): 2289-2303. doi: 10.1007/s12237-018-0424-5.  21.&amp;nbsp;&amp;nbsp; &amp;nbsp;Froelich BA, Daines DA. In hot water: effects of climate change on Vibrio-human interactions. Environ Microbiol 2020; 22(10): 4101-4111. doi: 10.1111/1462-2920.14967.  22.&amp;nbsp;&amp;nbsp; &amp;nbsp;Archer EJ, Baker-Austin C, Osborn TJ, Jones NR, Martínez-Urtaza J, Trinanes J, Oliver JD, González FJC, Lake IR. Climate warming and increasing Vibrio vulnificus infections in North America. Sci Rep 2023; 13(1): 3893. doi: 10.1038/s41598-023-28247-2.  23.&amp;nbsp;&amp;nbsp; &amp;nbsp;Brumfield KD, Chen AJ, Gangwar M, Usmani M, Hasan NA, Jutla AS, Huq A, Colwell RR. Environmental factors influencing occurrence of Vibrio parahaemolyticus and Vibrio vulnificus. Appl Environ Microbiol 2023; 89(6): e0030723. doi: 10.1128/aem.00307-23.  24.&amp;nbsp;&amp;nbsp; &amp;nbsp;Almagro-Moreno S, Martinez-Urtaza J, Pukatzki S. Vibrio infections and the twenty-first century. Adv Exp Med Biol 2023; 1404: 1-16. doi: 10.1007/978-3-031-22997-8_1.  25.&amp;nbsp;&amp;nbsp; &amp;nbsp;European Centre for Disease Prevention and Control (ECDC).  https://geoportal.ecdc.europa.eu/vibriomapviewer/   26.&amp;nbsp;&amp;nbsp; &amp;nbsp;Sunderkötter C, Becker K, Eckmann C, Graninger W, Kujath P, Schöfer H. S2k-Leitlinie Haut- und Weichgewebeinfektionen (Auszug aus: Paul-Ehrlich-Gesellschaft für Chemotherapie e.v.; Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen - Update 2018). J Dtsch Dermatol Ges 2019; 17(3): 345-371. doi: 10.1111/ddg.13790_g.  27.&amp;nbsp;&amp;nbsp; &amp;nbsp;Robert Koch-Institut (RKI).  https://www.rki.de/DE/Content/Infekt/NRZ/Konsiliar/Vibrionen/vibrionen_node.html  
 &amp;nbsp; 
   Das Auf und Ab der  Clostridioides-difficile -Infektion&amp;nbsp;(S.26)   
 &amp;nbsp;1.&amp;nbsp;&amp;nbsp; &amp;nbsp;Di Bella S, Sanson G, Monticelli J, Zerbato V, Principe L, Giuffrè M, Pipitone G, Luzzati R. Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options. Clin Microbiol Rev. 2024 Feb 29:e0013523. doi: 10.1128/cmr.00135-23.  2.&amp;nbsp;&amp;nbsp; &amp;nbsp;Weinke T, Beier D, Brestrich G, von Eiff C, Häckl D, Heinrich K, Moïsi J, Schley K. Epidemiology and risk factors of Clostridioides difficile infections in Germany: A health claims data analysis. Infect Dis Ther 2023; 12: 1299-1317. doi: 10.1007/s40121-023-00800-6.  3.&amp;nbsp;&amp;nbsp; &amp;nbsp;Brestrich G, Angulo FJ, Berger FK, Brösamle C, Hagel S, Leischker A, Lübbert C, Maechler F, Merbecks SS, Minarovic N, Moïsi JC, von Müller L, Reuken PA, Weinke T, Yu H, Mellmann A. Epidemiology of Clostridioides difficile infections in Germany, 2010-2019: A review from four public databases. Infect Dis Ther 2023; 12: 1057-1072. doi: 10.1007/s40121-023-00785-2.  4.&amp;nbsp;&amp;nbsp; &amp;nbsp;Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 1079-1084. doi: 10.1016/S0140-6736(05)67420-X.  5.&amp;nbsp;&amp;nbsp; &amp;nbsp;McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006; 12: 409-415. doi: 10.3201/eid1205.051064.  6.&amp;nbsp;&amp;nbsp; &amp;nbsp;Vonberg RP, Schwab F, Gastmeier P. Clostridium difficile in discharged inpatients, Germany. Emerg Infect Dis 2007; 13: 179-80. doi: 10.3201/eid1301.060611.  7.&amp;nbsp;&amp;nbsp; &amp;nbsp;Abdrabou AMM, Ul Habib Bajwa Z, Halfmann A, Mellmann A, Nimmesgern A, Margardt L, Bischoff M, von Müller L, Gärtner B, Berger FK. Molecular epidemiology and antimicrobial resistance of Clostridioides difficile in Germany, 2014-2019. Int J Med Microbiol 2021; 311: 151507. doi: 10.1016/j.ijmm.2021.151507.  8.&amp;nbsp;&amp;nbsp; &amp;nbsp;Abdrabou AMM, Sy I, Bischoff M, Arroyo MJ, Becker SL, Mellmann A, von Müller L, Gärtner B, Berger FK. Discrimination between hypervirulent and non-hypervirulent ribotypes of Clostridioides difficile by MALDI-TOF mass spectrometry and machine learning. Eur J Clin Microbiol Infect Dis 2023; 42: 1373-1381. doi: 10.1007/s10096-023-04665-y.  9.&amp;nbsp;&amp;nbsp; &amp;nbsp;Couturier J, Davies K, Barbut F. Ribotypes and new virulent strains across Europe. Adv Exp Med Biol 2024; 1435: 151-168. doi: 10.1007/978-3-031-42108-2_8.  10.&amp;nbsp;&amp;nbsp; &amp;nbsp;Verordnung zur Annpassung der Meldepflichten nach dem Infektionsschutzgesetz an die epidemische Lage (IfSG-Meldepflicht-Anpassungsverordnung – IfSGMeldAnpV) vom 18. März 2016. Bundesgesestzblatt 2016, Teil I Nr 13 vom 31. März 2016, 515.  https://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&amp;amp;start=//*%255B@attr_id=%27bgbl116s0515.pdf%27%255D   11.&amp;nbsp;&amp;nbsp; &amp;nbsp;Statistisches Bundesamt.  https://www.destatis.de/DE/Themen/Querschnitt/Demografischer-Wandel/demografie-mitten-im-wandel.html   12.&amp;nbsp;&amp;nbsp; &amp;nbsp;Robert Koch-Institut (RKI).  https://survstat.rki.de   13.&amp;nbsp;&amp;nbsp; &amp;nbsp;Heudorf U, Berres M, Dogan O, Steul KS. Meldepflicht für schwere Clostridiodes difficile- Infektionen – Daten aus Frankfurt am Main, 2014–2018. Bestandsaufnahme und Diskussion. Gesundheitswesen 2022; 84: 293-300. doi: 10.1055/a-1330-8293.  14.&amp;nbsp;&amp;nbsp; &amp;nbsp;Nationales Referenzzentrum (NRZ) für die Surveillance von nosokomialen Infektionen. Referenzdaten des Moduls CDI-KISS (Stand: Mai 2023).  https://www.nrz-hygiene.de/files/Referenzdaten/CDAD/202201_202212_CDI_Ref.pdf   15.&amp;nbsp;&amp;nbsp; &amp;nbsp;Kommission für Krankenhaushygiene und Infektionsprävention (KRINKO) beim Robert Koch-Institut (RKI). Hygienemaßnahmen bei Clostridioides difficile-Infektion (CDI). Bundesgesundheitsbl 2019; 62: 906–923. doi: 10.1007/s00103- 019- 02959-1.  16.&amp;nbsp;&amp;nbsp; &amp;nbsp;Schönherr S, Jung L, Lübbert C. Clostridioides difficile – Neue Erkenntnisse und Therapieempfehlungen. Dtsch Med Wochenschr 2023; 148: 752-758. doi: 10.1055/a-1970-9211.  17.&amp;nbsp;&amp;nbsp; &amp;nbsp;van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B, Krutova M, Norén T, Allerberger F, Coia JE, Goorhuis A, van Rossen TM, Ooijevaar RE, Burns K, Scharvik Olesen BR, Tschudin-Sutter S, Wilcox MH, Vehreschild MJGT, Fitzpatrick F, Kuijper EJ; Guideline Committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021; 27 Suppl 2: S1-S21. doi: 10.1016/j.cmi.2021.09.038.  18.&amp;nbsp;&amp;nbsp; &amp;nbsp;Vehreschild MJGT, Schreiber S, von Müller L, Epple HJ, Weinke T, Manthey C, Oh J, Wahler S, Stallmach A. Trends in the epidemiology of Clostridioides difficile infection in Germany. Infection 2023; 51: 1695-1702. doi: 10.1007/s15010-023-02044-5.  19.&amp;nbsp;&amp;nbsp; &amp;nbsp;Wendt S, Ranft D, de With K, Kern WV, Salzberger B, Lübbert C. Antibiotic Stewardship (ABS). Teil 2: Anwendung. Internist (Berl). 2020; 61: 475-486. doi: 10.1007/s00108-020-00763-7.  20.&amp;nbsp;&amp;nbsp; &amp;nbsp;Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) e. V. Strategien zur Sicherung rationaler Antibiotika-Anwendung im Krankenhaus. S3-Leitlinie (Stand: Januar 2019). Registernummer 092-001.  https://register.awmf.org/assets/guidelines/092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2020-02-abgelaufen.pdf   21.&amp;nbsp;&amp;nbsp; &amp;nbsp;Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, Döbele S, Tacconelli E. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis 2017; 17: 990-1001. doi: 10.1016/S1473-3099(17)30325-0. 
 &amp;nbsp; 
   Rubrik: Neue Substanzen    
   Rezafungin – ein neues Echinocandin-Antimykotikum&amp;nbsp;(S. 27)    
 1.&amp;nbsp;&amp;nbsp; &amp;nbsp;European Medicines Agency (EMA). Assessment report Rezzayo (Rezafungin). published online Oct 12, 2023.  https://www.ema.europa.eu/en/documents/assessment-report/rezzayo-epar-public-assessment-report_en.pdf  [10.04.2024]  2.&amp;nbsp;&amp;nbsp; &amp;nbsp;Robert Koch Institut (RKI). Mykosen (Pilzinfektionen) - Candidiasis; Stand 13.06.2023.   https://www.rki.de/DE/Content/InfAZ/P/Pilzinfektionen/Candida_spp.html  [10.04.2024]  3.&amp;nbsp;&amp;nbsp; &amp;nbsp;Groll, A.H. et al. S1 Leitlinie Diagnose und Therapie von Candida Infektionen: Gemeinsame Empfehlungen der Deutschsprachigen Mykologischen Gesellschaft (DMykG) und der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG) ICD 10: B37.-. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften eV, 2020.  https://register.awmf.org/assets/guidelines/082-005l_S1_Diagnose-Therapie-Candida-Infektionen_2020-09.pdf    4.&amp;nbsp;&amp;nbsp; &amp;nbsp;Garcia-Effron G. Rezafungin—Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins. J Fungi 2020;6(4):262. doi: 10.3390/jof6040262  5.&amp;nbsp;&amp;nbsp; &amp;nbsp;Fachinformation Rezzayo&amp;nbsp; (Rezafungin), Mundipharma, Stand 12/2023.  https://mundi-pharma-ger-d9.pid2-e1.investis.com/sites/mundi-pharma-ger/files/mundipharma-ger/products/RezzayoFachinformation.pdf    6.&amp;nbsp;&amp;nbsp; &amp;nbsp;Arendrup MC et al. Multicentre validation of a modified EUCAST MIC testing method and development of associated epidemiologic cut-off (ECOFF) values for rezafungin. J Antimicrob Chemother. 2022;78(1):185-95. doi: 10.1093/jac/dkac373.  7.&amp;nbsp;&amp;nbsp; &amp;nbsp;Hoenigl M et al. The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. Drugs. 2021;81(15):1703-29. doi:10.1007/s40265-021-01611-0  8.&amp;nbsp;&amp;nbsp; &amp;nbsp;Thompson GR et al. Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial. Clinical Infectious Diseases. 2020;73(11):e3647-e55. doi: 10.1093/cid/ciaa1380  9.&amp;nbsp;&amp;nbsp; &amp;nbsp;Thompson GR et al. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet. 2023;401(10370):49-59. doi: 10.1016/s0140-6736(22)02324-8 
 &amp;nbsp; 
 &amp;nbsp; 
   Aztreonam/Avibactam – eine neue Antibiotika-Kombination aus alten Bekannten&amp;nbsp;(S. 30)    
   1.&amp;nbsp;&amp;nbsp;&amp;nbsp; World Health Organization (WHO). WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. published online May 17, 2024.  https://iris.who.int/bitstream/handle/10665/376776/9789240093461-eng.pdf?sequence=1  [01.06.2024]    2.&amp;nbsp;&amp;nbsp; &amp;nbsp;European Medicines Agency (EMA). Assessment report Emblaveo&amp;nbsp; (Aztreonam/Avibactam). Stand: 21.03.2024.  https://www.ema.europa.eu/en/documents/assessment-report/emblaveo-epar-public-assessment-report_en.pdf  [01.06.2024]    3.&amp;nbsp;&amp;nbsp; &amp;nbsp;European Medicines Agency (EMA). Zusammenfassung der Merkmale des Arzneimittels Emblaveo (Aztreonam/Avibactam). published online May 07, 2024.  https://www.ema.europa.eu/de/documents/product-information/emblaveo-epar-product-information_de.pdf  [02.06.2024]    4.&amp;nbsp;&amp;nbsp; &amp;nbsp;Nordmann P et al. Recent Emergence of Aztreonam-Avibactam Resistance in NDM and OXA-48 Carbapenemase-Producing Escherichia coli in Germany. Antimicrob Agents Chemother 2021; 65(11): e0109021. doi: 10.1128/aac.01090-21    5.&amp;nbsp;&amp;nbsp; &amp;nbsp;Mauri C et al. The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases. Antibiotics (Basel) 2021; 10(8):1012. doi: 10.3390/antibiotics10081012    6.&amp;nbsp;&amp;nbsp; &amp;nbsp;Tamma PD et al. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect Dis 2023; published online first Jul 18, 2023. doi: 10.1093/cid/ciad428.       
 &amp;nbsp; 
     
 &amp;nbsp; 
                ]]>
            </content>

                            <updated>2024-07-19T11:00:00+02:00</updated>
                    </entry>

    
    
        <entry>
            <title type="text">Ausgabe 2.2024 | Zeitschrift für Infektionstherapie</title>
            <id>https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/ausgabe-2.2024-zeitschrift-fuer-infektionstherapie</id>
            <link href="https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/ausgabe-2.2024-zeitschrift-fuer-infektionstherapie"/>
            <summary type="html">
                <![CDATA[
                
                                            Hier finden Sie die aktuellen Literaturnachweise der Rubriken &quot;Übersicht&quot; mit dem Beitrag &quot;Update zur Therapie der diabetischen Fußinfektion&quot; und der Rubrik &quot;Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie&quot; mit dem Beitrag &quot;Reiseimpfungen: Dengue – Ein Neuer im Team...
                                        ]]>
            </summary>
            <content type="html">
                <![CDATA[
                   Rubrik: Übersicht   
   Update zur Therapie der diabetischen Fußinfektion (S.14)    
 1.&amp;nbsp;&amp;nbsp; &amp;nbsp;Senneville É. et al. IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-related Foot Infections (IWGDF/IDSA 2023). Clin Infect Dis. 2023; published online first Oct 2, 2023. doi: 10.1093/cid/ciad527.  &amp;nbsp;&amp;nbsp;  2.&amp;nbsp;&amp;nbsp; &amp;nbsp;El Sahly H. M. Diagnosis and Management of Diabetes-Related Foot Infections. NEJM Journal Watch; reviewing Senneville É. et al. Clin Infect Dis. 2023, Oct 2 2023. doi: 10.1093/cid/ciad/527. URL:  https://www.jwatch.org/na56648/2023/11/06/diagnosis-and-management-diabetes-related-foot-infections  [4.4.2024]  &amp;nbsp;&amp;nbsp;  3.&amp;nbsp;&amp;nbsp; &amp;nbsp;IWGDF/IDSA. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes. URL:  https://iwgdfguidelines.org/infection-guideline-2023/  [4.4.2024] 
 &amp;nbsp; 
   Rubrik: Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie   
   Reiseimpfungen: Dengue – Ein Neuer im Team der Reisemedizin (S. 17)    
 1.&amp;nbsp;&amp;nbsp; &amp;nbsp;Arbeitskreises Blut des Bundesministeriums für Gesundheit und Soziale Sicherung. Arboviren – durch Arthropoden übertragbare Viren. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2004; 47: 910-918. doi: 10.1007/s00103-004-0890-8. 
   2.&amp;nbsp;&amp;nbsp; &amp;nbsp;Mustafa MS, Rasotgi V, Jain S, Gupta V. Discovery of fifth serotype of dengue virus (DENV-5): a new public health dilemma in dengue control. Med J Armed Forces India 2015; 71(1): 67-70. doi: 10.1016/j.mjafi.2014.09.011. 
   3.&amp;nbsp;&amp;nbsp; &amp;nbsp;Simmons CP, Farrar JJ, Nguyen vVC, Wills B. Dengue. New Engl J Med 2012; 366(15): 1423-1432. doi: 10.1056/NEJMra1110265. 
   4.&amp;nbsp;&amp;nbsp; &amp;nbsp;Wilder-Smith A, Ooi EE, Horstick O, Wills B. Dengue. Lancet 2019; 393(10169): 350-363. doi: 10.1016/S0140-6736(18)32560-1. 
   5.&amp;nbsp;&amp;nbsp; &amp;nbsp;World Health Organization.  https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue  
   6.&amp;nbsp;&amp;nbsp; &amp;nbsp;Dammermann W, Haller IE, Singethan K, Vinnemeier CD, Hentschel F. Asymptomatic arbovirus and campylobacter infections in German travelers to Asia. Arch Virol 2023; 168(10): 254. doi: 10.1007/s00705-023-05870-y. 
   7.&amp;nbsp;&amp;nbsp; &amp;nbsp;Huits R, Angelo KM, Amatya B, Barkati S, Barnett ED, Bottieau E, Emetulu H, Epelboin L, Eperon G, Medebb L, Gobbi F, Grobusch MP, Itani O, Jordan S, Kelly P, Leder K, Díaz-Menéndez M, Okumura N, Rizwan A, Rothe C, Saio M, Waggoner J, Yoshimura Y, Libman M, Hamer DH, Schwartz E. Clinical characteristics and outcomes among travelers with severe dengue: a GeoSentinel analysis. Ann Intern Med 2023; 176(7): 940-948. doi: 10.7326/M23-0721. 
   8.&amp;nbsp;&amp;nbsp; &amp;nbsp;Robert Koch Institut.  https://survstat.rki.de/Content/Query/Create.aspx  (Stand: 16.11.2022) 
   9.&amp;nbsp;&amp;nbsp; &amp;nbsp;Falkenhorst G, Enkelmann J, Frank C, Lachmann R, Faber M, Pörtner K, Stark K: Zur Situation bei wichtigen Infektionskrankheiten – Reiseassoziierte Krankheiten 2019. Epidem Bull 2020; 50: 7-20. doi: 10.25646/7693. 
   10.&amp;nbsp;&amp;nbsp; &amp;nbsp;Bellini R, Michaelakis A, Petrić D, Schaffner F, Alten B, Angelini P, Aranda C, Becker N, Carrieri M, Di Luca M, Fălcuţă E, Flacio E, Klobučar A, Lagneau C, Merdić E, Mikov O, Pajovic I, Papachristos D, Sousa CA, Stroo A, Toma L, Vasquez MI, Velo E, Venturelli C, Zgomba M. Practical management plan for invasive mosquito species in Europe: I. Asian tiger mosquito (Aedes albopictus). Travel Med Infect Dis. 2020; 35: 101691. doi: 10.1016/j.tmaid.2020.101691. 
   11.&amp;nbsp;&amp;nbsp; &amp;nbsp;Frank C, Offergeld R, Lachmann R, Stark K, Schmidt-Chanasit J. Saison stechmückenübertragener Krankheitserreger beginnt. Epidem Bull 2023; 22: 3-7. doi: 10.25646/11492. 
   12.&amp;nbsp;&amp;nbsp; &amp;nbsp;European Centre for Disease Prevention and Control (ECDC). Autochthonous vectorial transmission of dengue virus in mainland EU/EEA, 2010-present.  https://www.ecdc.europa.eu/en/all-topics-z/dengue/surveillance-and-disease-data/autochthonous-transmission-dengue-virus-eueea  (Stand: 15.11.2023) 
   13.&amp;nbsp;&amp;nbsp; &amp;nbsp;Gjenero-Margan I, Aleraj B, Krajcar D, Lesnikar V, Klobucar A, Pem-Novosel I, Kurecic-Filipovic S, Komparak S, Martic R, Duricic S, Betica-Radic L, Okmadzic J, Vilibic-Cavlek T, Babic-Erceg A, Turkovic B, Avsic-Zupanc T, Radic I, Ljubic M, Sarac K, Benic N, Mlinaric-Galinovic G. Autochthonous dengue fever in Croatia, August-September 2010. Euro Surveill 2011, 16: 19805. doi: 10.2807/ese.16.09.19805-en. 
   14.&amp;nbsp;&amp;nbsp; &amp;nbsp;Pem-Novosel I, Vilibic-Cavlek T, Gjenero-Margan I, Kaic B, Babic-Erceg A, Merdic E, Medic A, Ljubic M, Pahor D, Erceg M. Dengue virus infection in Croatia: seroprevalence and entomological study. New Microbiol 2015; 38(1): 97-100. 
   15.&amp;nbsp;&amp;nbsp; &amp;nbsp;Paul-Ehrlich-Institut. Denguefieber-Impfstoffe.  https://www.pei.de/DE/arzneimittel/impfstoffe/denguefieber/dengue-node.html  (Stand: 15.11.2023) 
   16.&amp;nbsp;&amp;nbsp; &amp;nbsp;World Health Organization. Dengue vaccine: WHO position paper – September 2018. Wkly Epidemiol Rec 2018; 93: 457-476. 
   17.&amp;nbsp;&amp;nbsp; &amp;nbsp;Halstead SB, Dans LF. Dengue infection and advances in dengue vaccines for children. Lancet Child Adolens Health 2019; 3(10): 734-741. doi: 10.1016/S2352-4642(19)30205-6. 
   18.&amp;nbsp;&amp;nbsp; &amp;nbsp;Takeda GmbH. Fachinformation Qdenga®.  https://www.takeda-produkte.de/system/files/produkt-info/fachinformation-qdengar.pdf  (Stand: Dezember 2022) 
   19.&amp;nbsp;&amp;nbsp; &amp;nbsp;Rivera L, Biswal S, Sáez-Llorens X, Reynales H, López-Medina E, Borja-Tabora C, Bravo L, Sirivichayakul C, Kosalaraksa P, Martinez Vargas L, Yu D, Watanaveeradej V, Espinoza F, Dietze R, Fernando L, Wickramasinghe P, Duarte MoreiraJr E, Fernando AD, Gunasekera D, Luz K, Venâncioda Cunha R, Rauscher M, Zent O, Liu M, Hoffman E, LeFevre I, Tricou V, Wallace D, Alera M, Borkowski A. Three-year efficacy and safety of Takeda&#039;s Dengue vaccine Candidate (TAK-003). Clin Infect Dis 2022; 75(1): 107-117. doi: 10.1093/cid/ciab864. 
   20.&amp;nbsp;&amp;nbsp; &amp;nbsp; https://clinicaltrials.gov/study/NCT02747927  
   21.&amp;nbsp;&amp;nbsp; &amp;nbsp;Tricou V, Winkle PJ, Tharenos LM, Rauscher M, Escudero I, Hoffman E, LeFevre I, Borkowski A, Wallace D. Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults. Vaccine 2023; 41(47): 6999-7006. doi: 10.1016/j.vaccine.2023.09.049. 
   22.&amp;nbsp;&amp;nbsp; &amp;nbsp; https://clinicaltrials.gov/study/NCT03423173  
   23.&amp;nbsp;&amp;nbsp; &amp;nbsp;Tricou V, Essink B, Ervin JE, Turner M, Escudero I, Rauscher M, Brose M, Lefevre I, Borkowski A, Wallace D. Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study. PLoS Negl Trop Dis 2023; 17(3): e0011124. doi: 10.1371/journal.pntd.0011124. 
   24.&amp;nbsp;&amp;nbsp; &amp;nbsp;Tricou V, Eyre S, Ramjee M, Collini P, Mojares Z, Loeliger E, Mandaric S, Rauscher M, Brose M, Lefevre I, Folschweiller N, Wallace D. A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country. Vaccine 2023; 41(7): 1398-1407. doi: 10.1016/j.vaccine.2023.01.007. 
   25.&amp;nbsp;&amp;nbsp; &amp;nbsp;Kling K, Külper-Schiek W, Schmidt-Chanasit J, Stratil J, Bogdan C, Ramharter M, Rieke B, Wichmann O, Burchard G: STIKO-Empfehlung und wissenschaftliche Begründung der STIKO zur Impfung gegen Dengue mit dem Impfstoff Qdenga. Epidem Bull 2023; 48: 3-43. doi: 10.25646/11784. 
   26.&amp;nbsp;&amp;nbsp; &amp;nbsp;Takeda Pharmaceutical Company Limited.  https://www.takeda.com/newsroom/statements/2023/takeda-announces-voluntary-withdrawal-of-US-biologics-license-application-for-dengue-vaccine-candidate-TAK-003/  (Stand: 11.07.2023) 
 &amp;nbsp; 
     
 &amp;nbsp; 
                ]]>
            </content>

                            <updated>2024-04-17T11:00:00+02:00</updated>
                    </entry>

    
    
        <entry>
            <title type="text">Ausgabe 1.2024 | Zeitschrift für Infektionstherapie</title>
            <id>https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/ausgabe-1.2024-zeitschrift-fuer-infektionstherapie</id>
            <link href="https://shop.mhp-verlag.de/themen/infektionstherapie/infektio-literatur/ausgabe-1.2024-zeitschrift-fuer-infektionstherapie"/>
            <summary type="html">
                <![CDATA[
                
                                            Hier finden Sie die aktuellen Literaturnachweise der Rubrik &quot;Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie&quot; mit dem Beitrag &quot;Reiseimpfungen: Influenza – das Stiefkind der Reisemedizin?&quot; der Ausgabe 1.2024 der Zeitschrift für Infektionstherapie. 
                                        ]]>
            </summary>
            <content type="html">
                <![CDATA[
                   Rubrik: Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie   
   Reiseimpfungen: Influenza – das Stiefkind der Reisemedizin?&amp;nbsp;(S. 2)    
 
  1.&amp;nbsp;&amp;nbsp; &amp;nbsp;Forschungsgemeinschaft Urlaub und Reisen.  https://www.rnd.de/reise/reisen-2023-deutsche-planen-65-millionen-urlaubsreisen-reiselust-trotz-inflation-auf-vor-corona-3N7N23YJPVBXFFLZD4JVBCQUAE.html  
   2.&amp;nbsp;&amp;nbsp; &amp;nbsp;Ziegler CC. Travel-related illness. Crit Care Nurse Clin North Am 2013; 25(2): 333-340. doi: 10.1016/j.ccell.2013.02.015. 
   3.&amp;nbsp;&amp;nbsp; &amp;nbsp;Ratnam I, Black J, Leder K, Biggs BA, Gordon I, Matchett E, Padiglione A, Woolley I, Karapanagiotidis T, Gherardin T, Demont C, Luxemburger C, Torresi J. Incidence and risk factors for acute respiratory illnesses and influenza virus infections in Australian travellers to Asia. J Clin Virol 2013; 57(1): 54-58. doi: 10.1016/j.jcv.2013.01.008. 
   4.&amp;nbsp;&amp;nbsp; &amp;nbsp;Belderok SM, Rimmelzwaan GF, van den Hoek A, Sonder GJB. Effect of travel on influenza epidemiology. Emerg Infect Dis 2013; 19(6): 925-931. doi: 10.3201/eid1906.111864. 
   5.&amp;nbsp;&amp;nbsp; &amp;nbsp;Steffen R. Travel vaccine preventable diseases—updated logarithmic scale with monthly incidence rates. J Travel Med 2018; 25(1). doi: 10.1093/jtm/tay046. 
   6.&amp;nbsp;&amp;nbsp; &amp;nbsp;Grobusch MP, Weld L, Goorhuis A, Hamer DH, Schunk&amp;nbsp; M, Jordan S, Mockenhaupt FP, Chappuis F, Asgeirsson H, Caumes E, Jensenius M, van Genderen PJJ, Castelli&amp;nbsp; F, López-Velez R, Field V, Bottieau E, Molina I, Rapp C, Díaz Ménendez M, Gkrania-Klotsas E, Larsen CS, Malvy D, Lalloo D, Gobbi F, Florescu SA, Gautret P, Schlagenhauf P, EuroTravNet. Travel-related infections presenting in Europe: A 20-year analysis of EuroTravNet surveillance data. Lancet Reg Health Eur 2020; 1: 100001. doi: 10.1016/j.lanepe.2020.100001. 
   7.&amp;nbsp;&amp;nbsp; &amp;nbsp;Goeijenbier M, van Genderen P, Ward BJ, Wilder-Smith A, Steffen R, Osterhaus ADME. Travellers and influenza: risks and prevention. J Travel Med 2017; 24(1): taw078. doi: 10.1093/jtm/taw078. 
   8.&amp;nbsp;&amp;nbsp; &amp;nbsp;Ständige Impfkommission: Empfehlungen der Ständigen Impfkommission (STIKO) beim Robert Koch-Institut 2023. Epidem Bull 2023; 4: 3-68. doi: 10.25646/10829.4. 
   9.&amp;nbsp;&amp;nbsp; &amp;nbsp;Honce R, Schultz-Cherry S. Influenza in obese travellers: increased risk and complications, decreased vaccine effectiveness. J Travel Med 2019; 26(3): taz020. doi: 10.1093/jtm/taz020. 
   10.&amp;nbsp;&amp;nbsp; &amp;nbsp;Robert Koch Institut.  https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Influenza_saisonal.html  
   11.&amp;nbsp;&amp;nbsp; &amp;nbsp;Newman LP, Bhat N, Fleming JA, Neuzil KM. Global influenza seasonality to inform country-level vaccine programs: An analysis of WHO FluNet influenza surveillance data between 2011 and 2016. PLoS One 2018; 13(2): e0193263. doi: 10.1371/journal.pone.0193263. 
   12.&amp;nbsp;&amp;nbsp; &amp;nbsp;Boggild AK, Castelli F, Gautret P, Torresi J, von Sonnenburg F, Barnett ED, Greenaway CA, Lim PL, Schwartz E, Wilder-Smith A, Wilson ME, GeoSentinel Surveillance Network. Vaccine preventable diseases in returned international travelers: results from the GeoSentinel Surveillance Network. Vaccine 2010; 28(46): 7389-7395. doi: 10.1016/j.vaccine.2010.09.009. 
   13.&amp;nbsp;&amp;nbsp; &amp;nbsp;Chen LH, Leder K, Wilson ME. Business travelers: vaccination considerations for this population. Expert Rev Vaccines 2013; 12(4): 453-466. doi: 10.1586/erv.13.16. 
   14.&amp;nbsp;&amp;nbsp; &amp;nbsp;Kak V. Infections on cruise ships. Microbiol Spetr 2015; 3(4). doi: 10.1128/microbiolspec.IOL5-0007-2015. 
   15.&amp;nbsp;&amp;nbsp; &amp;nbsp;Millman AJ, Kornylo Duong K, Lafond K, Green NM, Lippold SA, Jhung MA. Influenza outbreaks among passengers and crew on two cruise ships: a recent account of preparedness and response to an ever-present challenge. J Travel Med 2015; 22(5): 306-311. doi: 10.1111/jtm.12215. 
   16.&amp;nbsp;&amp;nbsp; &amp;nbsp;Aoki Y, Amaya Dimas LDC. Influenza epidemic on a world cruise ship: a descriptive study. Travel Med Infect Dis 2021; 44: 102176. doi: 10.1016/j.tmaid.2021.102176. 
   17.&amp;nbsp;&amp;nbsp; &amp;nbsp;Balkhy HH, Memish ZA, Bafaqeer S, MA Almuneef. Influenza a common viral infection among Hajj pilgrims: time for routine surveillance and vaccination. J Travel Med 2004; 11(2): 82-86. doi: 10.2310/7060.2004.17027. 
   18.&amp;nbsp;&amp;nbsp; &amp;nbsp;Alfelali M, Barasheed O, Tashani M, Azeem MI, El Bashir H, Memish ZA, Heron L, Khandaker G, Booy R, Rashid H, Hajj Research Team. Changes in the prevalence of influenza-like illness and influenza vaccine uptake among Hajj pilgrims: a 10-year retrospective analysis of data. Vaccine 2015; 33(22): 2562-2569. doi: 10.1016/j.vaccine.2015.04.006. 
   19.&amp;nbsp;&amp;nbsp; &amp;nbsp;Safarpour H, Safi-Keykaleh M, Farahi-Ashtiani I, Bazyar J, Daliri S, Sahebi A. Prevalence of influenza smong Hajj pilgrims: a systematic review and meta-analysis. Diseaster Med Public Health Prep 2022; 16(3): 1221-1228. doi: 10.1017/dmp.2020.472. 
   20.&amp;nbsp;&amp;nbsp; &amp;nbsp;Alfelali M, Barasheed O, Badahdah AM, Bokhary H, Azeem MI, Habeebullah T, Bakarman M, Asghar A, Booy R, Rashid H, Hajj Research Team. Influenza vaccination among Saudi Hajj pilgrims: Revealing the uptake and vaccination barriers. Vaccine 2018; 36(16): 2112-2118. doi: 10.1016/j.vaccine.2018.03.007. 
   21.&amp;nbsp;&amp;nbsp; &amp;nbsp;Robert Koch Institut. Ergebnisbericht 2023: OKaPII - Onlinebefragung von Klinikpersonal zur Influenza-Impfung (22.08.2023).  https://www.rki.de/DE/Content/Infekt/Impfen/Forschungsprojekte/OKaPII/Ergebnisbericht_2023.pdf  
   22.&amp;nbsp;&amp;nbsp; &amp;nbsp;Brehm TT, Jordan S, Addo MM, Ramharter M, Kreuels&amp;nbsp; B. Attitudes, practices, and obstacles towards influenza vaccination for international travelers among travel health advisors in Germany: a questionnaire-based survey. Travel Med Infect Dis 2022; 45: 102233. doi: 10.1016/j.tmaid.2021.102233. 
 
   26.&amp;nbsp;&amp;nbsp; &amp;nbsp;Takeda Pharmaceutical Company Limited.  https://www.takeda.com/newsroom/statements/2023/takeda-announces-voluntary-withdrawal-of-US-biologics-license-application-for-dengue-vaccine-candidate-TAK-003/  (Stand: 11.07.2023) 
 &amp;nbsp; 
     
 &amp;nbsp; 
                ]]>
            </content>

                            <updated>2024-02-13T11:00:00+01:00</updated>
                    </entry>

    
</feed>
